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ABSTRACT 
 This thesis includes studies on N-, mucin type O-, and glycosaminoglycan 
(GAG)-linked glycosylation in human biospecimens. Glycosylation plays a central role in 
biological processes, including protein folding, immune surveillance, and regulation of 
cell growth. The structures of GAG are regulated in a tissue-specific manner. Heparan 
sulfate (HS) and chondroitin sulfate (CS) are the two types of GAGs targeted in this 
thesis. 
 Human leukocytes express both CS and HS GAGs with CS being the more 
abundant type; however, little is known regarding the properties and structures of GAG 
chains, their ranges of variability among normal subjects, and changes in structure 
associated with disease conditions. We measured the relative and absolute disaccharides 
abundances of HS and CS for purified B, T, NK cells, monocytes, and 
polymorphonuclear leukocytes (PMNs) using size exclusion chromatography-mass 
spectrometry (SEC-MS). We found that all leukocytes express HS chains with levels of 
sulfation more similar to heparin than to organ-derived HS. In addition, CS abundances 
  x 
varied considerably in a leukocyte cell type specific manner. Therefore, our results 
established the ranges of GAG structures expressed on normal leukocytes as well as 
necessary for subsequent inquiry into disease conditions. 
 Glioblastoma (GBM) accounts for 30% of human primary brain tumors. It is 
deadly and highly invasive. In past decades, most GBM research focused on 
pathophysiological changes in genome. There remains a dearth of knowledge regarding 
alterations in glycomics, glycoproteomics, and proteomics during GBM tumorigenesis. 
Therefore, we developed a comprehensive platform for high-throughput sample 
preparation with surface digestion for tissue microarrays, LC-MS/MS data dependent 
acquisition, and semi-automated data analysis to integrate glycomics, glycoproteomics, 
and proteomics for different grade of tumor and different subtypes of GBM. By analyzing 
GBM tissue microarrays, we found tumor grade and subtype specific changes to the 
expression of biomolecules. We also identified approximately 100 site-specific N- and 
mucin type O-glycosylations, the majority of which were previously unreported. Overall, 
our results improved the fundamental understandings about GBM pathogenesis.  
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Chapter 1. Introduction  
1.1 Protein glycosylations 
1.1.1Common classes of animal glycans and glycosylations 
 Protein glycosylation is one of the most common and functionally important 
forms of post-translational modifications (PTMs), which plays a central role in many 
biological processes and pathways, including protein folding (1,2), signaling pathways 
(3,4), immune surveillance (5-7), inflammatory responses (8), cancer progression (9,10). 
As illustrated in Figure 1.1, glycosylation generates different types of glycans and 
glycoconjugates, which are generally linked to lipids or proteins. In mammals, the major 
monosaccharide building blocks for complex glycan include glucose (Glu), galactose 
(Gal), mannose (Man), xylose (Xyl), fucose (Fuc), N-acetylgalactosamine (GalNAc), N-
acetylglucosamine (GlcNAc), 5-N-acetylneuraminic acid (Neu5Ac, or sialic acid), 
glucuronic acid (GlcA), and iduronic acid (IdoA). Glycosphingolipids, glycolipid 
conjugates, are the major components of the outer layer of cell plasma membrane. Protein 
can be glycosylated by the covalently attachment of glycans to the protein backbone 
through either amide linkage (N-linkage) to the side chain of asparagine or glycosidic 
linkage (O-linkage) to the side chain of serine or threonine. N-glycans share a common 
pentasaccharide core structure (Man3+GlcNAc2), which can be further extended into 
high-mannose, hybrid, and complex structures (11,12). The terminal of hybrid and 
complex N-glycans can be further decorated with GlcNAc, Gal, Fuc, and sialic acid. 
There are different types of O-glycans such as O-Man, O-Fuc, O-GlcNAc, mucin type O-
glycans and glycosaminoglycans (GAGs). Mucin type O-glycans are extended from 
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GalNAc into eight common branched core structures (12,13). GAGs of the chondroitin 
sulfate and heparan sulfate classes are linear polysaccharide chains initiated with a 
tetrasaccharide linker (GlcA-Gal-Gal-Xyl) and elongated with repeating disaccharides as 
building blocks. Such GAG chains can be further modified by sulfation and 
epimerization, producing substantial structural heterogeneity (14-16). A glycoprotein 
composed of a core protein with multiple GAG chains covalently attached to the Serine 
residue is known as a proteoglycan (PG). 
 
Figure 1.1 Common classes of vertebrate glycans and glycoconjugates, adapted from 
reference (10) 
 
1.1.2 Cancer associated alteration in N- and O-glycosylations 
 Alterations in glycosylation associated with cancer pathogenesis and 
tumorigenesis were described more than sixty years ago (17). As shown in Figure 1.2, the 
N-glycosylation	
Mucin type O-glycosylation	
Proteoglycans and GAGs	
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most-widely observed cancer-specific changes for N- and O-glycosylation include an 
increase in sialylation (3,18,19), sialyl Lewis x (SLe
x
) and sialyl Lewis a (SLe
a
) (20), 
truncated mucin type O-linked glycan antigens including T, Tn, and STn (17,21,22), 
branched fucosylated N-glycans (23), core fucosylated N-glycans (3,19), and bisecting 
GlcNAc N-glycans (19,24). A detailed discussion about the relationship between GAG 
and cancer pathogenesis will be covered later in this chapter. Aberrant glycosylations 
have been found to play fundamental roles in numerous steps of cancer development such 
as interfering the cell-cell adhesion as well as cell-extracellular matrix (ECM) interaction, 
stimulating receptor tyrosine kinase (RTK) signaling pathways and promoting 
angiogenesis (10). For example, the terminal sialic acid residue of integrin glycans have 
been reported to impair the cell-ECM interaction by inhibiting integrin interactions with 
ECM constituents including fibronectin and collagen type IV, and promoting cancer 
metastasis phenotypes (25-27).  
 
Figure 1.2 Aberrant N- and O-glycosylations associate with cancer progression 
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 In this thesis, we investigated the integrated glycomics, glycoproteomics, and 
proteomics alterations in N-glycosylated proteins, mucin type O-glycosylated proteins, and 
GAG-linked proteoglycans during glioblastoma tumorigenesis by mass spectrometry. The 
structures of released glycosaminoglycans were analyzed and used to produce glycomics 
data. Shotgun proteomics experiments were performed to identify and quantify proteins from 
complex biological samples with a combination of high performance liquid chromatography 
(HPLC) with mass spectrometry (MS). Glycoproteomics data were extracted from shotgun 
proteomics since we were able to identify intact glycopeptides containing N-glycans and 
mucin type O-glycans from MS/MS tandem spectra.  
1.2 Quantitative glycomics for heparan sulfate (HS) and chondroitin sulfate (CS)  
1.2.1 HS/CS and structure heterogeneity 
1.2.1.1 HS and CS, two major components of the glycosaminoglycan family  
 Heparan sulfate (HS) and chondroitin sulfate (CS) are the two major components 
of the GAG family, which are covered in this thesis.  The GAG disaccharide units of CS 
and HS are composed of a hexamine group (either N-acetylated or N-sulfated) and an 
uronic acid group (either glucuronic acid, GlcA or iduronic acid, IdoA). Heparan sulfate 
proteoglycans (HSPGs) are decorated with mainly HS chains while chondroitin sulfate 
proteoglycans (CSPGs) are modified with mainly CS chains.  
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Figure 1.3 Glycosaminoglycans (GAGs) family, adapted from chapter 16 of 
Essentials of Glycobiology, 2
nd
 edition 
 
1.2.1.2 The structures of HS/CS are highly modified  
 The structures of HS/CS are extremely heterogeneous due to the numerous 
modifications that occur during biosynthesis and through ECM enzymatic cleavages that 
occur after biosynthesis. HS chains are biosynthesized as nascent repeating units of 
(4GlcAβ1-4 GlcNAcα1-) attached to PG serine residues via a xylosyl tetrasaccharide 
linker (28,29). The nascent chains are processed by a series of enzymes including N-
deacetylase/N-sulfotransferase, glucuronyl C5-epimerase, and O-sulfotransferases. 
Such O-sulfation may occur at the 2O-position of HexA, the N-, 3O-, and/or 6O-positions 
of GlcN. As shown in Figure 1.4, mature HS chains contain defined domains with high 
(NS), low (NA) and intermediate (NS/NA) sulfation, the patterns of which are organ-
specific (30). This tissue-specific structure can be seen in compositions of disaccharides 
and oligosaccharides from different tissues and cell types (31,32). CS chains are 
biosynthesized as repeating units of (4GlcAβ1-3GalNAcβ1-) attached to PG serine 
residues via a tetrasaccharide linker of the same monosaccharide structure as with HS 
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(33-35). The nascent chains are processed by a series of enzymes including dermatan 
glucuronyl C5-epimerases, and O-sulfotransferases. Mature chains may contain sulfation 
at the 2O-position of HexA, the 4O-and/or 6O-positions of GalNAc. 
 Post-synthetic HS/CS modifications can occur in the extracellular matrix. The 
dynamic structure alterations in HS/CS by extracellular enzymes are involved in tumor 
progression and metastasis (36-41). Among those extracellular GAG-modifying enzymes, 
heparanase and 6-O-sulfatases (Sulfs) are widely studied. Heparanase is a glucuronidase 
that hydrolyzes the glycosidic bonds between glucosamine and GlcA residues, producing 
relatively long oligosaccharide free chains. Sulfs can selectively remove 6-O-sulfate 
groups and tune the sulfation pattern of NS domains.  
 
Figure 1.4 Different domains of HS chain that vary in the extent of sulfation and 
epimerization, adapted from chapter 16 of Essentials of Glycobiology, 2
nd
 edition 
 
1.2.1.3 The structure-biological function correlation of GAG 
 The structure modifications of GAG by biosynthesis enzymes as well as ECM 
enzymes heparanase and Sulfs correlate with the tissue developmental and disease states.  
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GAGs and PGs play essential roles in embryonic development, nutritional metabolism, 
injury repair, and morphogenesis (39,42). Additionally, GAGs and PGs are involved in 
numerous cancer-related processes including cell proliferation and growth, invasion, 
metastasis, and angiogenesis (42-45). Generally speaking, PGs execute their biological 
functions through the interaction among GAGs and growth factors and growth factor 
receptors (28). The highly sulfated GAG NS domain of cell surface HSPGs is preferred 
to bind the growth factors with higher affinity, thereby acting as a co-receptor domain for 
the upregulation of downstream RTK signaling cascades. The extracellular PGs can also 
serves as dynamic growth factor reservoirs to actively sequester growth factor from tissue 
surface, thereby inhibiting the RTK signaling pathway.  
1.2.1.4 GAG and PG based approaches of cancer therapy  
 Low molecular weight heparin tinzaparin (46) was found to inhibit angiogenesis 
in vivo. Modified heparan sulfate and chondroitin sulfate have also been studied as 
potential cancer therapeutics through the inhibition of GAG biosynthetic pathways and 
ECM remodeling enzymes (47-49). Another therapeutic strategy for interfering with 
GAG function is the use of inhibitory GAG-binding peptides (50). For example, the 
peptide P4 that has a high binding affinity to hyaluronan inhibits angiogenesis.  GAGs 
and PGs also serve as tumor specific targets for toxin delivery. For example, syndecans-1 
was recently explored as an antibody-mediated toxin delivery target for myeloma cells 
(51).  
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1.2.2 HS/CS disaccharide analysis 
 Since the balance of biosynthetic and extracellular remodeling activities is critical 
in fine tuning the human physiology as well as cancer biology, we need to investigate the 
dynamic alterations in GAG structures in order to fully understand the roles of PGs under 
different biological matrices and scenarios. The most commonly and widely used 
analytical method to study the structure of GAGs is disaccharide analysis. As shown in 
Figure 1.5, GAGs can be depolymerized into disaccharide units through either nitrous 
acid deaminative cleavage (52) or bacterial lyases (53). For nitrous acid 
depolymerization, disaccharides containing either an anhyromannose (HS) or 
anhyrotalose (CS) are generated, thereby resulting in the loss of information on the 
substituent on the hexosamine nitrogen. For lyase digestion, the product disaccharides 
contain an unsaturated uronic acid residue, thereby losing the stereochemistry of the C5 
position for uronic acid. Thus, these two methods are complementary. We decided to use 
the lyase depolymerization method to perform tissue surface digestions because of its 
mild reaction conditions. Nitrous acid depolymerization method is time-consuming 
involving multiple chemical derivatization steps and more importantly, the addition of 
low-pH nitrous acid onto the tissue surface may cause tissue disruption. Heparin lyases 
and chondroitinase ABC were used to cleaved HS and CS, respectively, in our 
experiments. The common digested disaccharides for HS/CS are listed in Figure 1.6 with 
the nomenclature proposed by Dr. Roger Lawrence (54). 
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Figure 1.5 Depolymerization method for HS, adapted from reference (16)  
 
 
Figure 1.6 Nomenclature for HS and CS disaccharides with the Lawrence code 
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1.2.3 Chromatography interfaces for the quantification of HS/CS disaccharides 
 Liquid chromatography (LC) can be coupled with mass spectrometry analysis, 
allowing precise quantification of HS/CS disaccharides. The quantification discussed 
here is all based on the chromatographic peak areas for each disaccharide. The robust and 
reproducible LC retention time is the key for reliable quantification. Different 
concentrations of commercial HS/CS disaccharides are used to establish the standard 
quantification curve that will be used for transformation of mass spectral signal 
intensities into absolute quantity.  
1.2.3.1 Size exclusion liquid chromatography (SEC)  
 SEC is a separation technique based on the molecular size of the molecules. 
Molecules do not bind to the chromatography resins as they pass through the column. 
SEC is widely used for the separation of biomolecules that are sensitive to changes in pH, 
metal concentration, and harsh environmental conditions. Separations can be performed 
in the presence of detergent, urea, and guanidine hydrochloride at high or low ionic 
strength. Our lab has developed an SEC-MS method to separate and quantify HS/CS 
disaccharides from numerous biological sources such as tissues, blood cells, and 
histological slides (31,55,56). The SEC-MS method is extremely robust and reproducible; 
however, it is time-consuming as each LC run requires about 3 hours. Additionally, the 
sensitivity of this method is not promising as the typical LC flow rate is 16 μl/min, 
significantly larger than used in the nano-scale chromatography. These disadvantages of 
SEC-MS limit its application for high throughput analyses. 
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1.2.3.2 Porous graphitized carbon liquid chromatography (PGC)  
 PGC is known for its strong retention for polar and anionic molecules. It separates 
molecules based on their polarity and hydrophobicity. Since HS/CS disaccharides are 
polar and highly acidic, the retention time for disaccharides increases as the number of 
the sulfate groups increases. We and other labs have already investigated the PGC-MS 
method for HS/CS separation and quantification (57-59). PGC enables extremely high 
resolving power for isomer separation. However, the dynamic range for the HS 
disaccharide separation is not optimized. We observed that D2S6 that contains 3 sulfate 
groups for molecular weight less than 600 Da tends to bind the PGC resin tightly, thereby 
causing difficulty in its elution from the column. In addition, PGC is relatively difficult to 
maintain as the complex biological matrix can easily contaminate the column. Therefore, 
the retention time shifts over time. 
1.2.3.3 C18 reversed phase liquid chromatography (RPLC)  
 RPLC is a chromatography separation method based on the analyte 
hydrophobicity. RPLC is one of the most robust liquid separation techniques, and is 
widely used in the proteomics LC-MS/MS analysis. Since HS/CS disaccharides are 
hydrophilic and acidic, they elute from the void volume of the column due to their low 
binding ability to the column. In order to increase the hydrophobicity of HS/CS 
disaccharides, hydrophobic function groups are linked to glycans through reductive 
amination chemistry (60,61). The derivatized HS/CS disaccharides were subjected to C18 
RPLC-MS analysis (62-64). The biggest limitation for RPLC analysis of HS/CS 
disaccharides is the high demand for high-throughput sample preparation workflow. We 
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tend not to conduct chemical derivation for high-throughput tissue microarray 
application. 
1.2.3.4 C18 reversed phase ion pairing liquid chromatography (RPIP)  
 Another strategy to increase the binding ability of native HS/CS disaccharides to 
the C18 RPIP resin is through addition of ion pairing reagents into the mobile phase. The 
ion pairing reagents have an ionic end and a nonpolar tail. The nonpolar end of the 
reagent binds strongly to the hydrophobic C18 stationary phase, leaving its ionic end to 
attract the opposite charge of analytes. Therefore, amine based ion pairing reagents like 
dibutyl amine, tributyl amine, and triethyl amine are used for HS/CS disaccharide 
separation (65,66) as they all contain a positively charged ionic end. RPIP is also a high-
resolution separation chromatography for HS/CS isomers. However, the high 
concentration of amine reagent in the mobile phase could pose potential contamination 
issue for the mass spectrometer. 
1.2.3.5 Hydrophilic interaction liquid chromatography (HILIC)  
 HILIC is used to separate glycans based on their size and hydrophilicity. 
Therefore, it is a good candidate to separate native HS/CS disaccharides. Our lab recently 
developed a HILIC-MS method to analyze heparin lyase as well as nitrous acid 
depolymerized HS disaccharides (67). The dynamic range for HS/CS disaccharides and 
the separation resolution for isomers are both improved with HILIC chromatography. In 
order to improve the sensitivity of LC-MS, we can scale down the flow rate to the nano 
HPLC range. We therefore decided to develop a nano-fluidic HILIC-LC-MS/MS method 
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for analyzing extremely low abundances of HS recovered from the TMA tissue surface. 
The method development will be discussed in detail in Chapter 4.  
1.3 Quantitative proteomics  
1.3.1 MS-based shotgun/bottom up proteomics  
1.3.1.1 General workflow for the shotgun/bottom up proteomics  
 MS-based shotgun/bottom-up proteomics is widely used for protein identification, 
quantification, PTM analysis, characterization of protein-protein interactions, and 
network study. The typical workflow for a shotgun/bottom-up proteomics experiment is 
illustrated in Figure 1.7. Firstly, proteins are extracted from homogenized tissues, 
cultured cells, or body fluids followed by proteolytic digestion into peptides. Trypsin is 
the most commonly used protease. Depending on the goal of the experiment, the 
proteolytic peptides can be subjected into pre-fractionation, affinity enrichment and/or 
multidimensional separation. These fractions are then analyzed one by one by reversed 
phase C18 liquid chromatography linked to mass spectrometry (C18 LC-MS). Tandem 
MS/MS is performed to fragment selected peptides. The generated MS and MS/MS data 
are then searched against a database for peptide sequence identification. Finally, the 
assigned peptide sequences are matched to proteins. Downstream applications such as 
protein quantification, protein network mapping, and PTM identification can be 
performed with the corresponding bioinformatics and biostatistics inputs. 
 Unlike the extraction of proteins/glycans from homogenized tissues or cells, we 
and another group developed a tissue surface digestion workflow for histological slides 
(55,68,69). Trypsin can be applied onto the tissue surface either manually or with a 
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chemical chip inkjet printer CHIP-1000, followed by the extraction of digested peptides 
from tissue surface with LESA (liquid extraction surface analysis). LESA was developed 
as a novel micro-liquid extraction technique from solid surfaces, which is subjected for 
the examination of drug spatial distribution (70). A detailed description of this tissue 
surface digestion workflow will be presented in the chapter 4.  
 
Figure 1.7 General workflow for shotgun/bottom up proteomics, adapted from 
reference (71) 
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1.3.1.2 MS analyzer and detector option for high speed proteomics data acquisition  
 Generally speaking, the mass analyzers either belong to the scanning and ion-
beam mass spectrometers such as time-of-flight (TOF) and quadrupole or the trapping 
mass spectrometers such as Orbitrap, quadrupole ion trap and Fourier-transform ion 
cyclotron resonance (FT-ICR). As listed in Table 1.1, ion trap and Orbitrap mass 
analyzers are favored for shotgun/bottom-up proteomics high-throughput data 
acquisition. The ion trap instruments provide extremely fast scan speed and high 
sensitivity, significantly increasing the number of protein hits with the proteomics 
database search. However, the mass resolution, mass accuracy, and the quality of tandem 
MS/MS spectra are not optimal for ion trap instruments, which are featured by Orbitrap 
mass analyzer. During the past decade, the Orbitrap instruments evolved quickly with 
significant improvements for higher scan rate and detection sensitivity (72).   
Table 1.1 Comparison of mass spectrometry instruments for shotgun proteomics, 
adapted from reference (73) 
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 In our study, we used a ThermoFisher Q Exactive plus (QE+) MS instrument for 
the shotgun proteomics as well as glycomics data acquisition. As shown in Figure 1.8, 
QE+ is an Orbitrap/Quadrupole hybrid mass spectrometer. The stacked-ring RF lens 
allows for increased sensitivity. The hyperQuad mass filter with advanced quadrupole 
technology provides increased ion transmission and superior isolation window shape. The 
C-trap features highly efficient ion transfer to the Orbitrap mass analyzer. Higher energy 
collision dissociation (HCD) fragmentation is performed for tandem MS/MS. In 
summary, this state-of-the-art mass spectrometer provides optimized resolving power (up 
to 280,000 @ m/z 200), scan rate (up to 12 Hz at 17,500 resolution @ m/z 200), mass 
accuracy (<1ppm), sensitivity, and broad dynamic range.  
Figure 1.8 Schematics of the QE+ mass spectrometer 
 
1.3.1.3 Proteome pathway analysis 
 MS-based shotgun/bottom-up proteomics provide detailed information toward the 
identification, quantification, and characterization of proteins that constitute a proteome. 
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Bioinformatics and biostatistics analysis on a measured proteome can be used to model 
protein interaction networks, cellular functions, and spatial localization (74-76). For 
example, Gene Ontology and PFAM databases can be used to identify enriched cellular 
components, protein domains, biological processes and functions.  In addition, proteins of 
interest can be mapped to network and pathway databases (STRING, KEGG, IPA) for 
visualization in the particular functional contexts. 
 Ingenuity pathway analysis (IPA) is used to map proteome data to biological 
processes, networks, and pathways (77). We performed IPA core analysis for our 
proteomics dataset. The core analysis is the process of mapping data to the IPA 
knowledge base, creating molecular algorithmically generated networks, dividing data 
into diseases and biological functions, and determining over represented either 
upregulated or downregulated signaling and metabolic canonical pathways. The top 
regulator effect networks and canonical pathway networks can be exported from IPA. In 
addition, IPA identifies the most promising and relevant biomarker candidates from the 
experimental datasets.  
1.3.2 Differential stable isotope labeling quantification 
 Stable isotope labeling-based quantification is applicable based on the fact that a 
peptide labeled with stable isotopes is different from the unlabeled peptide only in the 
molecular mass without appreciably changing the chemical property of the peptide during 
liquid chromatography (78). The labeled samples are mixed with unlabeled samples and 
subjected to C18 LC-MS/MS simultaneously. The labeled and unlabeled peptides co-
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elute, allowing precise comparison for relative quantification among samples. The stable 
isotopes can be introduced to the samples metabolically, chemically, and enzymatically. 
1.3.2.1 Metabolic labeling  
 
15
N-labeling was first used to study the protein phosphorylation in bacteria and 
allowed quantitative comparison between only two samples (79). The stable-isotope-
labeled essential amino acids in the cell culture (SILAC) was later developed and used as 
a high-throughput quantitative technique (80). In general, heavy and light forms of 
Arginine or Lysine were incorporated during cell culture prior to sample preparation and 
trypsin digestion, which significantly reduces sample handling. 
1.3.2.2 Chemical labeling  
 The isotope-coded affinity tag (ICAT) was developed by Dr. Steven Gygi (81). 
For the ICAT approach, the Cysteine residues on the peptides or proteins are specifically 
derivatized with either zero or eight deuterium atoms. The cysteine-derived peptides are 
further enriched by the biotin affinity and subjected to MS analysis. ICAT tags are 
specifically bound to Cysteine, which is not a common amino acid in the protein 
sequence and thus effectively reduces the sample complexity. However, this property 
might also limit its application toward proteins that lack Cysteine residues.  
 Unlike SILAC and ICAT that quantify peptides based on MS1 analysis, isobaric 
mass tags such as tandem mass tag (TMT) (82) and isobaric tags for relative and absolute 
quantification (iTRAQ) (83) quantify the peptide abundance based on the tandem MS 
spectra as the different mass tags can only be distinguished upon peptide fragmentation. 
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The TMT and iTRAQ tags label the primary amines in the samples through N-
hydroxysuccinimide (NHS) chemistry. 
 ICAT, TMT, and iTRAQ labeling quantitative methods can handle 8-10 
multiplexed samples, which significantly speed up the data acquisition and workflow 
throughput.  
1.3.2.3 Enzymatic labeling  
 The isotope 
18
O can also be introduced into peptides during proteolytic digestion 
by trypsin or Glu-C (84,85) in the presence of H2
18
O. Incorporation of 
18
O into the C-
terminus of peptides leads to a mass shift of 2 Da. Since trypsin and Glu-C digestion 
introduce two oxygen atoms, thereby resulting in a total 4 Da mass shift. This 4 Da shift 
is generally sufficient for mass spectrometer for isotopomer differentiation. Therefore, 
trypsin and Glu-C are favored over Lys-N and the other proteolytic enzymes.  
1.3.3 Proteomics label free quantification  
1.3.3.1 Spectral counting vs feature based strategy 
 Although differential stable isotope labeling allows accurate protein 
quantification, it’s not quite applicable to large-scale proteomics analysis of clinical 
samples. Therefore, the label free quantification methods have been developed to fully 
utilize the features of MS and MS/MS spectra. Two widely used label-free quantification 
methods are spectral counting and precursor peptide peak intensity measurement (feature 
based), as shown in Figure 1.9. In the spectral counting approach, the number of 
identified tandem MS spectra for a protein of interest is compared among multiple LC-
MS/MS runs to achieve protein quantification. This strategy is possible due to the 
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empirical observation that the number of tandem MS spectra of a particular protein 
increases with an elevated amount of the corresponding protein (86,87). Obviously, the 
outcome of spectral counting relies on the data dependent acquisition settings and 
dynamic exclusion for precursor ions. The feature-based approach measures the 
chromatographic peak area of each precursor ion and uses it for quantification. The 
rationale behind this is based on the linear correlation between the protein abundance and 
its chromatographic peak area (88,89).  
 We applied the feature-based label-free quantification strategy for our proteomics 
dataset. In general, the five key steps are raw data signal processing, feature finding, LC 
retention time alignment among runs, feature identification by MS/MS and database 
searching, and summation of the chromatographic peak area of identified 
features/peptides for a particular protein. 
1.3.3.2 Progenesis QI for proteomics label free quantification  
 We used commercial Progenesis LC-MS software to conduct proteomics label-
free quantification. A detailed performance test for Progenesis is described in chapter 4. 
The ability to align the retention time of multiple LC-MS runs is critical for precise peak 
picking and peptide abundance measurements. Progenesis automatically scans the whole 
dataset and chooses the best candidate as reference run for alignment. User can also 
designate the reference run. Since Progenesis provides wavelet-based peak picking, it can 
process low-resolution MS data as well (90). The built-in statistical tools including 
ANOVA, power analysis and q-value calculation for false discovery rate are extremely 
helpful for identifying differentially expressed proteins among samples. 
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Figure 1.9 Feature based and spectral counting pipelines for proteomics label free 
quantification, adapted from reference (90) 
 
1.4 Glycoproteomics  
1.4.1 Glycopeptide enrichment strategies 
 Simultaneous elucidation of the glycan structure, glycosylation site, and the 
glycopeptide sequence by mass spectrometry is critical to reveal the biological functions 
of protein glycosylation. One of the major analytical challenges for comprehensive 
glycoproteomics characterization for protein glycosylation is caused by the much lower 
abundances of glycopeptides than non-glycosylated peptides. In order to solve this 
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problem, various glycopeptide enrichment methods have been explored. As shown in 
Figure 1.10, N-glycopeptides can be enriched by lectin affinity chromatography, HILIC 
chromatography, TiO2 affinity chromatography, hydrazide chemistry, reductive 
amination chemistry, and boronic acid chemistry. The last three enrichment methods 
involve enzymatic release of N-glycans from peptides and immobilized beads, leaving 
behind non-glycosylated peptides. This enrichment strategy is not suitable for tandem MS 
analysis of glycopeptides. Therefore, they are not discussed in details in this thesis. 
Enrichment for O-glycopeptides is analytically challenging; however, selective 
enrichment prior to mass spectrometry analysis for sialylated O-glycopeptides is 
practical. 
 
Figure 1.10 The common enrichment methods for N-glycopeptides, adapted from 
reference (91) 
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1.4.1.1 Lectin affinity enrichment  
 Lectins can bind to distinct glycan epitopes, allowing affinity enrichment. There 
are at least 160 known lectins, among which more than 60 types are commercially 
available (92). Some lectins, such as jacalin (JAC) (93), wheat germ agglutinin (WGA) 
(94), and concanavalin (Con A) (95), are shown to have broad binding specificity 
towards glycans, whereas others are specifically bound to particular structures of glycan. 
For example, α-2,6 linked terminal sialic acid can be recognized and purified by 
Sambucus nigra lectin (SNA) (92). Depending on the purpose of research, a variety of 
lectins can be chosen to capture protein glycoforms. 
1.4.1.2 HILIC enrichment 
 Offline HILIC enrichment with Zic-HILIC column or cartridge is rapidly 
developed for glycoproteomics field (96,97). Our lab developed an online HILIC chip-
based LC-MS/MS method for N-glycopeptide enrichment (98). The packed HILIC resin 
is TSK Amide-80. HILIC chromatography preferentially enriches N-glycopeptides over 
O-glycopeptides as the mucin type O-glycans are typically smaller than N-glycans. 
Additionally, non-glycosylated peptides with certain degree of hydrophilicity are also 
enriched.  
1.4.1.3 PGC enrichment  
 Like HILIC, PGC also has high binding affinity for glycans, which can be used as 
either offline (99) or online enrichment with micro-fluidic chip packed with PGC resin 
(100-103), or online LC separation stationary phase (104). 
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1.4.1.4 TiO2 enrichment 
 TiO2 is used to enrich anionic phosphorylated proteins or peptides. Similarly, it 
can selectively enrich sialic acid-containing N- and O-glycopeptides (105,106). 
Neuraminidase is used to cleave bound sialic acid and release the non-sialylated 
glycopeptides from TiO2, followed by mass spectrometry analysis.  
1.4.1.5 Modified hydrazide enrichment for sialylated glycopeptides 
 Sialylated glycopeptides are subjected to mild periodate oxidation, followed by 
solid phase hydrazide enrichment. The mild formic acid hydrolysis is used to cleave off 
sialic acid, releasing non-sialylated peptides from hydrazide beads (107). This method is 
also helpful for selective enrichment of sialylated N- and O-glycopeptides.  
1.4.2 Tandem MS for glycopeptides 
 Another huge challenge for glycoproteomics is to retain the intact attached glycan 
and fragment the peptide backbone with excellent sequence coverage simultaneously. 
Unlike N-glycosylation, O-glycosylation does not occur to a known consensus sequence. 
Additionally, O-glycosylated peptides are heterogeneous as there are typically multiple 
modification sites on the peptide sequence. Therefore, it is extremely difficult to 
accurately assign the O-glycosylation site(s) with poor sequence coverage and sugar 
neutral loss. In order to better understand the fragmentation mechanisms and preferences, 
different fragmentation methods are compared.  
1.4.2.1 Collision induced dissociation (CID) and HCD 
 During the process of collision induced dissociation (CID) of glycopeptides, the 
attached glycans are preferentially fragmented, thereby resulting in high abundances of 
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oxonium ions (108-110). On the other hand, few peptide backbone fragmentations are 
observed. Although CID can provide the information on the glycan composition, it is not 
a preferred method for glycopeptide fragmentation due to the minimal peptide backbone 
sequence coverage.  
 HCD fragmentation is a variant of CID introduced by Thermo-Fisher Scientific 
for their Orbitrap mass spectrometer instrument (111). It has become a widely used 
fragmentation method for the analysis of labile PTMs such as phosphorylation (112) and 
glycosylation (104,113). Lower NCE (normalized collision energy) is applied to cleave 
glycans while higher NCE is used to fragment the peptide backbone. With alternating low 
and high NCE, the sequence of glycopeptide and the composition of glycans can be 
determined. However, the precise assignment for glycosylation site for mucin type O-
glycopeptide with this strategy is not possible. We also performed HCD for proteomics 
data acquisition.  Surprisingly, we observed high signal intensities of glycopeptides. With 
a NEC 30 setting, N-glycosylated peptides with short high mannose N-glycans were 
fragmented with good sequence coverage. The sequence coverages for O-glycosylated 
peptides were satisfactory; however, the accurate assignment of some glycosylation sites 
remains ambiguous. Our glycoproteomics data will be shown in chapter 5.   
1.4.2.2 Electron activated dissociation  
 Electron capture dissociation (ECD) (114) and electron transfer dissociation 
(ETD) (115) are recently developed MS/MS fragmentation techniques that retain the 
labile post-translational modifications and produce preferentially c and z
•
 type fragment 
ions. As shown in Figure 1.11, multiply protonated peptides are irradiated by low energy 
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electrons (<0.2ev). Capture of an electron by a pronated peptide ion leads to peptide 
backbone fragmentation via a nonergodic process. In ECD, the electrons are generated by 
a heated dispenser cathode. In ETD, the electrons are transferred from radical anion 
reagents. 
 
Figure 1.11 Schematic of ECD fragmentation, adapted from reference (115) 
 
 ECD and ETD are now widely used for glycoproteomics in order to increase the 
sequence coverage for both O-and N-glycosylated peptides and to assign the 
glycosylation sites correctly (110,116-121). Currently, ECD is commercially available 
only on FTICR mass spectrometers, whereas ETD is more widely available on a variety 
of commercial instruments. CID and ETD can also be applied alternately to reveal the 
glycan structure, glycosylation site, and the glycopeptide sequence simultaneously (122).  
 
  
27 
Chapter 2. Comparative Glycomics of Human Leukocyte Glycosaminoglycans 
2.1 Introduction  
2.1.1 Tissue and cell type specific expression of glycosaminoglycans 
 Heparan sulfate (HS) chains are biosynthesized as nascent repeating units of 
(4GlcAβ1-4 GlcNAcα1-) attached to proteoglycan (PG) serine residues via a xylosyl 
tetrasaccharide linker (28,29). The nascent chains are processed by a series of enzymes 
including N-deacetylase/N-sulfotransferase, glucuronyl C5-epimerase, and O-
sulfotransferases. Such O-sulfation may occur at the 2O-position of HexA, the N-, 3O-, 
and/or 6O-positions of GlcN. Mature HS chains contain blocks of high, low and 
intermediate degrees of sulfation, the patterns of which are organ-specific (30). This 
tissue-specific structure can be seen in compositions of disaccharides and 
oligosaccharides from different tissues and cell types (31,32). 
 Chondroitin/dermatan sulfate (CS/DS) chains are biosynthesized as repeating 
units of (4GlcAβ1-3GalNAcβ1-) attached to proteoglycan (PG) serine residues via a 
tetrasaccharide linker of the same monosaccharide structure as with HS (33-35). The 
nascent chains are processed by a series of enzymes including dermatan glucuronyl C5-
epimerases, and O-sulfotransferases. Mature chains may contain sulfation at the 2O-
position of HexA, the 4O-and/or 6O-positions of GalNAc. Chains with a significant 
percentage of their uronic residues in IdoA form are referred to as DS. In CS/DS, IdoA 
residues may occur isolated among repeats containing GlcA, or alternating with GlcA 
repeats, or in long blocks of disaccharides. 
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 Although HS chains vary in their overall extent of sulfation, a highly sulfated 
non-reducing end domain has been observed regardless of the total level of chain 
sulfation for organ-derived HS (123). CS chains also vary in structure depending on the 
tissue and the developmental state. Thus, characteristic CS sulfation patterns are 
associated with cartilage (124,125), skin (126,127), and neural (128) tissues. The 
expression of domains of CS/DS structure has been observed in a variety of tissues 
(129,130). 
Experiments on organ tissues do not provide information regarding the structure 
of GAGs made by single cell types owing to the heterogeneous cell populations making 
up each organ. As a result, comparatively little is known regarding detailed structures of 
GAGs expressed in a cell-type specific manner. Such information would help shed light 
on the mechanisms whereby GAG structure reflects both normal and disease-specific 
phenotypes. We sought to determine patterns of GAG expression in primary cells isolated 
from each individual. By collecting data in this manner we avoided questions of 
variability due to genetic makeup versus cell phenotype. 
2.1.2 GAG expression in hematopoietic cells 
 The expression of GAGs in leukocytes was demonstrated in studies in which 
isolated hexosamine or alcian-blue-positive material co-migrated with CS analyzed by 
electrophoresis or chromatography (131,132). One line of evidence shows that leukocyte 
GAGs were predominantly 4-O-sulfated CS (133) and associated with granules (134). 
PMN GAGs are composed primarily of 4-sulfated CS with a minor proportion of HS 
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(135). T lymphocytes were found to both biosynthesize and secret GAGs consisting 
largely of CS with smaller amounts of HS (136). 
 Serglycin proteoglycan mRNA is transcribed in hematopoietic lineage cells 
(137,138). Serglycin-bound CS has been described as the major GAG present in 
hematopoietic cells (139). Connective tissue mast cells contain serglycin, a major 
function of which is to package lytic factors including chymases, tryptases, 
carboxypeptidases, histamine and serotonin (139). Among leukocytes, PMNs, CD8+ 
cytotoxic T lymphocytes (CTLs) and NK cells are known to contain large amounts of 
lytic proteins in their granules. The serglycins in the granules of CTLs and PMNs are 
stored or secreted in a regulated manner. In addition, serglycins are secreted 
constitutively in monocytes, B cells, CD4+ and CD8+ T cells (140). 
 Among leukocytes, PMN populations, consisting primarily of neutrophils, have 
been found to contain CS-type PGs on their surfaces (141). Serglycin has been found to 
be present in the Golgi apparatus of PMN more so than in mature granules, and is thought 
to help in transport of neutrophil elastase (142,143). Active, inhibitor resistant, neutrophil 
elastase released from degranulating PMN binds CS and HS proteoglycans on the cell 
surface in a high-capacity, low-affinity manner (144). Proteases are found on the surfaces 
of freshly isolated monocytes and B lymphocytes, including matripase (145). Cell surface 
cathepsin B on cytotoxic lymphocytes inactivates perforin molecules released during 
degranulation thereby preventing damage to the cells (146). It is therefore of interest to 
determine the extent to which GAG chains of myeloid derived cell lineages including 
PMNs and mononcytes resemble those expressed by lymphoid derived lymphocytes. 
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2.1.3 Hematopoietic cell GAGs and disease 
 Much of the information regarding proteoglycan expression and hematopoietic  
cell diseases has come through use of an enzyme-linked immunosorbent assay (ELISA) 
for syndecan-1(CD138). Syndecan-1 has been reported to be absent from all 
hematopoietic cells other than those of the B cell lineage where its expression helps 
classify B cell lymphomas including Hodgkin’s lymphoma, AIDS Burkitt lymphomas 
and systemic AIDS diffuse large cell lymphoma (147). In addition, syndecan-1 is 
elevated in sera of multiple myeloma patients and appears to enhance angiogenesis, 
growth and metastasis of tumor cells (148,149). Levels of syndecan-1 are elevated in 
chronic lymphocytic leukemia patients and are associated with shorter survival (150). 
Systemic lupus erythematosis, a disease characterized by loss of B cell tolerance, is also 
associated with elevation of circulating syndecan-1 on B cells (151). Because the results 
are from ELISA specific to syndecan-1, there is no information on structures of GAG 
chains. In addition, among leukocytes, syndecan-4 mRNA was detected only in 
inactivated CD4+ and CD8+ T cells. Its expression was increased in several lymphoma 
cell lines (152). Little is known about the structure of syndecan-4 in these cell lines. 
 Spurred by the correlations between disease states and proteoglycan expression, 
we sought to improve the understanding of the patterns of GAG expression by 
leukocytes. We applied mass spectrometric methods for GAG to define cell specific 
phenotypes in greater detail than available previously. Our goal was to define GAG 
structural expression patterns on leukocytes from normal donors as a basis for developing 
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understanding of disease states. Our work shows unexpected expression patterns for CS 
and HS GAGs on leukocytes. 
2.2 Experimental Section 
2.2.1 Materials  
 Fresh human buffy coat was purchased from Research Blood Components, LLC 
(Boston, MA). Dextran solution was prepared by dissolving 20 g dextran (Sigma-Aldrich, 
St. Louis, MO) and 9 g NaCl in 1000 ml distilled water. The B Cell Isolation Kit II 
(human), Pan T Cell Isolation Kit (human), NK cell Isolation kit (human) and Pan 
Monocyte Isolation Kit (human) were purchased from Miltenyi Biotec (Boston, MA). 
Heparin lyase I was purchased from New England Biolabs (Andover, MA) and heparin 
lyases II and III were generous gifts from Prof. Jian Liu (UNC Eshelman School of 
Pharmacy, USA). Recombinant human syndecan-4 was purchased from R&D Systems 
(Minneapolis, MN). Heparan sulfate sodium salt from bovine kidney (HSBK) was from 
Sigma-Aldrich. Heparan sulfate sodium salt from porcine intestinal mucosa (HSPIM) 
was purchased from Celsus Laboratories (Cincinnati, OH). 
2.2.2 Isolation of PMNs and PBMCs from human buffy coat 
 One unit of human blood produced approximately 50 ml buffy coat. The buffy 
coat was allowed to separate into two sections after adding 50 ml dextran solution for 30 
min at room temperature, followed by drawing off the upper section. The lower layer was 
centrifuged for 10 mins at 200x g at room temperature and the pellets were re-suspended 
in 20 ml phosphate buffered saline (PBS) without calcium and magnesium. A volume of 
10 ml Ficoll-paque Plus (GE healthcare) was then added and the mixture was centrifuged 
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at 300x g at room temperature for 30 min. Subsequently, the white layer of cells on the 
top of the Ficoll-paque layer was carefully transferred into a 50 ml tubes. The cells in the 
white layer are PBMCs containing lymphocytes and monocytes. The PBMC layer was 
washed twice using PBS without calcium and magnesium and then stored at 4 °C. The 
pellets under the ficoll layer corresponded to the mixture of red blood cells and PMNs. 
The pellets were re-suspended in 10 ml endoxin-free water and mixed continuously for 
30 s, followed by addition of 10 ml 1.8% NaCl. The cells were centrifuged at 200x g for 
3 min at 10 °C and the pellets were re-suspended in 10 ml 0.2% NaCl. The suspension 
was mixed continuously for 15 s and 10ml 1.8% NaCl was added. The suspension was 
centrifuged at 200x g for 3 min at 10 °C to pellet PMN. The pellets were re-suspended 
with PBS containing 0.9 mM calcium and 0.5 mM magnesium. The cell numbers of 
PBMCs and PMNs were counted in three fields of a hemacytometer (Fisher Scientific). 
Cell viabilities were observed to be greater than 95%. Cells were counted using the 
formula: cell number/ml = total cell numbers in three fields * 3333.3 * dilution factor. 
2.2.3 Isolation of B cells, T cells, NK cells, and monocytes by negative selection kits 
 Taking B cell isolation for example, human B cells are isolated by depletion of 
non-B cells (negative selection). The commercial kit protocols were followed for this 
purpose. 
2.2.4 GAG extraction from cells  
 Purified B cells, T cells, NK cells, monocytes, PMNs and PBMCs were divided 
into three aliquots and GAGs were extracted from cells in parallel except Donor 2 with 
GAGs extraction from only two aliquots from each purified cell populations. A 1 ml 
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volume of cell lysis buffer (PBS buffer with 1% Triton X-100) was added to the cell 
pellets immediately after purification, followed by end-over-end mixing overnight at 4 
°C. A 0.1 ml cell lysis buffer containing 0.2 mg protease from Streptomyces 
griseus (Sigma-Aldrich) was added and the lysate was incubated for 12 h at 55 °C with 
end-over-end mixing. After heat inactivation of the protease at 100 °C, the buffer was 
adjusted to 2 mM MgCl2 and 300 mU of benzonase (Sigma-Aldrich) was added. The 
sample was incubated at 37 °C for 3 hours. The samples were adjusted to 0.5 M NaOH 
and mixed end-over-end overnight at 4 °C. The pH of the samples was lowered to 5.0 
using acetic acid. The samples were centrifuged at 20,000x g for 5 min at room 
temperature and the supernatants were transferred to a clean tube. The supernatants were 
diluted with 2–3 ml distilled water and then applied to a DEAE-Sepharose column. The 
DEAE-Sepharose columns were prepared by adding 1.4 ml DEAE-Sepharose (Sigma-
Aldrich) to a 10 ml empty column (Bio-Rad). GAGs were eluted with 2.5 ml of 1 M 
NaCl, 20 mM NaOAc pH 6.0, and the eluates were desalted using PD-10 columns (GE 
healthcare). Finally, each sample was divided into three aliquots (one for heparin lyase I–
III digestion and one for chondroitinase ABC digestion) and dried overnight in a vacuum 
concentrator. 
2.2.5 Enzyme digestion for heparan sulfate and chondroitin sulfate  
 For HS digestion, one aliquot of GAG was digested with 100 mU of heparin lyase 
I, 10 mU of heparin lyase II, and 10 mU of heparin lyase III in a final volume of 30 μl of 
20 mM Tris/HCl buffer pH7.4, in the presence of 5 mM CaCl2. The digestion was 
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incubated at 37 °C for 5 h and a second aliquot of the lyase I, II, III mixture was added 
prior to overnight incubation at 37 °C (31). 
 For CS digestion, one aliquot of GAG was digested with 20 mU of chondroitinase 
ABC in a final volume of 30 μl of 25 mM Tris/HCl buffer pH8.0, in the presence of 5 
mM NH4OAc. The digestion was incubated at 37°C for 5 h and a second aliquot of 
chondroitinase ABC was the added prior to overnight incubation at 37°C. 
2.2.6 SEC-MS analysis  
 The SEC column (Superdex
™
 peptide PC 3.2/30) was purchased from GE 
healthcare. The mobile phase for disaccharides analysis was 90% 12.5 mM formic acid, 
pH adjusted to 4.4 using ammonium hydroxide, 10% acetonitrile. The liquid 
chromatography was conducted using a Waters Acquity UltraPerformance LC system 
and disaccharides were analyzed using an Applied Biosystems QSRAR Pulsar-I mass 
spectrometer operating in the negative mode, as previously described (31). A 20 pmol 
quantity of ΔHexA2S-GlcNCoEt (6S) (Iduron) was added to all samples as an internal 
standard. An Ionization efficiency correction factor for each disaccharide relative to 
nonsulfated disaccharide D0A0 was applied to calculation of disaccharide abundances. 
The abundances of disaccharides were normalized to 10 million cells. 
2.2.7 Tandem Mass spectrometry for D0a4/Doa6 mixture 
 Using SEC-MS, the elution time for monosulfated disaccharide D0a4/D0a6 is 99 
min. Collision energy (−30 eV) was applied from 95.5 min to 102.5 min. A set of 
D0a4/D0a6 disaccharide standards mixtures (1:0, 3:1, 2:1,1:1,1:2, 1:3, and 0:1) was made 
using commercial standards (V-Labs) and injected separately for SEC-tandem mass 
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spectrometry analysis to establish a relationship between D0a4/(D0a4+D0a6) and 
Y1 ion/(Y1+Z1) ion. 
2.3 Results 
2.3.1 Heparan sulfate and chondroitin sulfate quantity in human leukocytes  
 Aliquots of GAGs extracted from B cells, T cells, NK cells, monocytes, 
peripheral blood mononuclear cells (PBMCs) and PMNs were digested exhaustively into 
disaccharides using either heparin lyase I, II and III or chondroitinase ABC. As 
determined from the abundances of the chromatographic peaks, heparin lyase digestion as 
>95% complete and chondroitinase digestion was >99% complete. 
 
Figure 2.1 Representative extracted ion chromatograms (EICs) for HS and CS 
disaccharides and monosaccharide for human leukocytes observed using SEC-MS 
(A) Δ4,5- unsaturated HS disaccharides from T cells from Donor 2. 1, D0A0; 2, D0S0; 3, 
D0A6/D2A0; 4, D0S6/D2S0; 5, D2S6. D2A6 is not shown here because it was very low in 
abundance. Note that traces 2 and 4 were observed as two peaks due to in-source losses of SO3. 
These losses were corrected for in the quantitative calculations. (B) 4,5-unsaturated CS 
disaccharides and monosaccharide from PMNs from Donor 2. 1′, D0a0; 2′, GalNAcSO3; 3′, 
D0a4/D0a6; 4′, D0a10/D2a6/D2a4. Note that trace 3′ is observed as two peaks due to in-source 
loss of SO3. These losses were corrected for in the quantitative calculations. Trace 2′ was also 
observed as two peaks due to in-source fragmentation of D0A6/D2A0. 
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 A set of representative size exclusion chromatography-mass spectrometry (SEC-
MS) extracted ion chromatograms (EICs) for HS and CS data acquired on T cells and 
PMNs is shown in Figure 2.1. The HS Δ4,5-unsaturated disaccharides released using 
heparin lyases I, II, and III digestion are shown in Figure 2.1A. The abundances of CS 
Δ4,5-unsaturated disaccharides and GalNAcSO3 monosaccharide digested using 
chondroitinase ABC are shown in Figure 2.1B. The saccharides were identified based on 
their elution times and mass using SEC-MS (31).  
 The ion abundances of Δ4,5-unsaturated disaccharides of HS from different 
leukocytes cell populations are shown in Figure 2.2A-D. The data for each donor 
demonstrate that HS profiles differ among the leukocytes cell populations; thus, it is clear 
that HS expression differs among leukocyte populations at a given time. The PBMC 
population, representing lymphocytes, monocytes and dendritic cells, has the highest total 
HS expression for three of the four donors. Excluding PBMC, HS expression follows the 
trend T cells, B cells>monocytes, NK cells>PMNs as shown in Figure 2.2E. Figure 2.2F 
gives absolute quantities (pmol) of total HS disaccharides per 10
7
 cells that were 
calculated using external HS disaccharides standards, confirming HS expression trend 
among leukocytes demonstrated in Figure 2.2E.  
 The ion abundances of CS saccharides from leukocyte cell populations are shown 
in Figure 2.3A-D. For each donor, we detected CS expression level differences among 
leukocytes cell populations that showed a consistent trend (Figure 2.3E). The absolute 
quantities (pmol) of total CS saccharides per 10
7
 cells that were calculated using external  
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Figure 2.2 Summary of ion abundances of HS Δ4,5-unsaturated disaccharides and 
total HS disaccharides from leukocytes from four donors 
HS total ion abundance is the sum of six Δ4,5-unsaturated disaccharides ion abundances and is 
normalized to 10 million cells. The number of B cells isolated from donor 1(A) was too low that 
was below the limit of quantification. Triplicates samples of extracted GAGs were digested using 
heparin lyases I, II and III for donors 1(A), 2(B) and 4(D) for each cell population except B cells 
in which duplicates were used. Duplicates of extracted GAGs were digested with heparin lyases I, 
II and III for donor 3(C) for each cell population. Box-whisker plots of HS total disaccharides ion 
abundances in counts (E) and HS total disaccharides quantities in pmols (F), summarized from 
four donors. Box plot (E) shows that the median (range) for HS total disaccharides ion 
abundances in counts was 1.34*105 (1.16*105–3.94*105), 2.71*106 (2.52*106 –7.23*106), 
1.65*106 (4.62*105–1.02*107), 1.24*106 (1.93*105–1.49*106), 5.26*105 (8.53*104–4.17*106) 
and 6.25*105(4.25*105 –7.16*106) for the PMN, PBMC, T, B, NK and monocyte, respectively. 
Box plot (F) shows that the median (range) for HS total disaccharides quantities in pmol was 
94.03 (30.41–110.48), 680.80 (634.51–824.63), 418. 88 (117.81–2562.87), 316.50 (49.77–
376.93), 133.69 (22.41–1078.462) and 157.34 (114.42–953.50) for the PMN, PBMC, T, B, NK 
and monocyte, respectively. The horizontal bar at the two ends represents the smallest and largest 
values. The values within the box are the first quartile (Q1), median and the third quartile (Q3). 
Outlier values are indicated using crosses, defined as 1.5 (Q3-Q1) below Q1 or above Q3. The 
outliers in (E) and (F) represent values from donor 3 duplicates. 
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Figure 2.3 Summary of CS saccharides ion abundances and total abundance from 
leukocytes from four donors 
CS total ion abundance was calculated from the sum of 3 Δ4,5-unsaturated disaccharides, 3 
saturated disaccharides and GalNAcSO3 and was normalized per 10 million cells. Triplicate 
samples of extracted GAGs were digested using chondroitinase ABC for donors 1(A), 2(B) and 
4(D) for each population except for B cells for which duplicates were acquired. Duplicates of 
extracted GAGs were digested using chondroitinase ABC for donor 3(C) for each cell population. 
CS total ion abundances in counts (E) and CS total saccharides quantities in pmols (F) 
summarized from four donors. Box plot (E) shows that the median (range) for CS total ion 
abundances in counts was 1.06*107 (4.69*106–2.58*107), 1.56*107 (1.06*107 –3.91*107), 
2.99*106 (1.51*106–8.14*106), 1.97*106 (3.80*105–2.49*106), 5.79*106 (2.47*106–2.14*107) 
and 1.26*107(7.19*106 –7.75*107) for the PMN, PBMC, T, B, NK and monocyte, respectively. 
Box plot (F) shows that the median (range) for CS total saccharides quantities in pmols was 
2898.65 (733.94–4410.74), 2953.09 (1495.21–5517.81), 330.63(208.66–1307.76), 276.69(67.37–
354.40), 817.80(354.10–3425.85) and 2838.23(1041.45–10890.79) for the PMN, PBMC, T, B, 
NK, and monocyte, respectively. Box-whisker plot notation was the same as shown in the Figure 
2.2 legend. 
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CS disaccharides standards shown in Figure 2.3F, giving very similar CS expression 
trend observed in Figure 2.3E. For three of four donors, PMNs and monocytes 
populations displayed significantly higher total CS expression than lymphocytes. The 
donor 1 NK cells showed a high level of CS expression relative to the other three donors, 
skewing the overall trend in CS expression (Figure 2.3E) 
 In order to determine the abundance of DS, we used chondroitinase B to digest 
GAGs from B cells, T cells, NK cells, monocytes, PBMCs and PMNs. This enzyme 
cleaves regions of the CS/DS chains that contain at least two adjacent disaccharide units 
with IdoA residues (153). We did not detect any disaccharide products from B cells, T 
cells, NK cells and PBMCs. The abundances of disaccharides in chondroitinase B digests 
of CS/DS from monocytes and PMS was less than 1% of that observed with 
chondroitinase ABC. 
2.3.2 Comparison of total heparan sulfate and chondroitin sulfate in human 
leukocytes 
 Figure 2.4A-E compares the total HS and CS ion abundances for different 
leukocyte populations in four donors. Among the four donors there was a consistent trend 
in expression of total GAG. For these donors, GAG level per 10
7
 cells was highest for 
PMN, PBMC and monocytes. The bulk of the GAG was CS but significant HS levels 
were detected for all populations. The total GAG in lymphocytes (T, B and NK cells) 
were significantly lower than monocytes and PBMC. In addition, for all cell populations, 
CS was considerably higher in abundance than HS (Figure 2.4F). The CS/HS ratio is 
highest for PMN, followed by monocytes and NK cells. The B and T cell population  
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Figure 2.4 Summary of HS and CS ion abundances from leukocytes in 4 donors 
(E) Total HS and CS ion abundances summarized from four donors. Box plots show the median 
(range) were 1.07*107 (4.81*106–2.59*107), 1.91*107 (1.31*107 –4.69*107), 3.11*106 (1.97*106–
1.33*107), 2.81*106 (3.80*105–3.83*106), 7.59*106 (2.67*106–2.23*107) and 1.33*107(7.78*106 –
8.07*107) for the PMN, PBMC, T, B, NK and monocyte, respectively. (F) CS/HS ratio 
summarized from four donors. The median (range) were 66 (37.2–185.9), 4.6 (3.9–9.9), 3.1 (0.3–
4.0), 2.0 (1.0–12.3), 23.2 (1.9–40.2), 17.7 (11.8–65.1) for the PMN, PBMC, T, B, NK and 
monocyte, respectively. The outliers in (F) represent values from donor 3 duplicates. 
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showed the lowest CS/HS ratios. These data are consistent with the conclusion of cell 
type-specific expression of CS and HS among leukocyte classes. 
 
 
Figure 2.5 Summary of each HS disaccharides relative ion abundance from 
leukocytes in 4 donors  
 
2.3.3 Highly sulfated HS in leukocytes  
 In addition to absolute GAG quantity in different cell types, we investigated 
relative HS chain composition (Figure 2.5). The relative ion abundances of Δ4,5-
unsaturated disaccharides yielded important information regarding HS structure. Organ-
derived HS chains have characteristic disaccharide compositions (30). The ion 
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abundances of highly sulfated disaccharides (D2S6) are less than 10% for even then 
relatively highly sulfated organ-derived HS other than from intestinal mucosa (31,123). 
Our data show that D2S6 relative ion abundances for HS from bovine kidney (HSBK) 
and syndecan-4 are within this range (Figure 2.6). The level of D2S6 in HS from porcine 
intestinal mucosa (HSPIM) was ~40%, as expected since it is structurally similar to 
heparin. To our surprise, we detected high ion abundances of D2S6 (~30%) in all 
leukocyte classes from the four donors (Figure 2.5). We further elucidated this trend by 
calculating the overall HS sulfation levels, reflected by the number of sulfate groups per 
100 disaccharides (Figure 2.7). For all leukocyte cell populations (except NK cells and 
monocytes in donor 4), the number of sulfate groups per 100 disaccharide units was 
higher than that of HSBK (Figure 2.6). The number of sulfate groups per 100 
disaccharides for HSBK is similar to HS from other organs from a variety of species 
(31,123). In addition, T cells have highest overall sulfation level (with median of 130 
sulfate groups per 100 disaccharides) among leukocytes in all 4 donors (Figure 2.7E). 
2.3.4 Shorter CS chain in PMNs than in different cell types of PBMCs  
 Figure 2.8 shows the relative ion abundances of saccharides released by 
chondroitinase ABC digestion. Because of the high abundance of CS in leukocytes, we 
were able to quantify the saturated mono- and disaccharides deriving from the non-
reducing end of the parent chains. Lymphocytes (B cells, T cells and NK cells) and 
monocytes showed very similar profiles, with >90% of D0a4/D0a6 in all 4 donors. We 
note that PMNs in three (donors 2,3 and 4) out of four donors contain lower D0a4/D0a6 
% but higher GalNAcSO3 % than other cell types of leukocytes. As CS chains may 
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terminate with GalNAcSO3 or a HexA at the non-reducing end, we calculated the CS 
relative chain length by using the ratio of Δ4,5-unsaturated to saturated saccharides. As 
shown in Figure 2.9, PMN showed significantly lower CS relative chain lengths than 
those of other leukocytes; B cells had the longest CS chains. From Figure 2.3, monocytes 
and PMN have similar abundances of CS. The fact that PMN have considerably shorter 
chains indicates that there are many more chain-modifying proteins for PMN relative to 
monocytes. 
 
Figure 2.6 Relative ion abundances of Δ4,5-unsaturated HS disaccharides from 
recombinant syndecan-4 and HSBK 
The ion abundance of D2S6 is less than 10%, shown in the top panel. The number of sulfate 
groups per 100 disaccharides (dp2s) in syndecan-4 and HSBK is less than 90, shown in bottom 
panel. HSPIM, which is structurally similar to heparin, has 44% 
D2S6 and 194 sulfate groups per 100 dp2. 
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Figure 2.7 Summary of the number of sulfate groups per 100 HS disaccharides 
(dp2s) from 4 donors 
(E) Box-whisker plot of the data. The median (range) were 113 (90-141),131 (125-142),132 (122-
145),121 (106-132),113 (58-143), and 113 (74-130) for PMN, PBMC, T, B, NK and monocyte, 
respectively. The box-whisker plot notation was the same as described in the Figure 2.2 legend. 
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Figure 2.8 Summary of each CS disaccharide or GalNAcSO3 relative ion 
abundances from leukocytes in 4 donors 
(E) D0a4/D0a6% summarized from four donors. Box plots show the median (range) were 70.5% 
(69.3%–83.8%), 96.3% (81.9%–96.6%), 94.2% (78.3%–94.6%), 96.2% (69.5%–97.5%), 95.9% 
(79.8%–97.3%), and 94.9% (92.2%–96.2%) for the PMN, PBMC, T, B, NK and monocyte, 
respectively. (F) GalNAcSO3% summarized from four donors. The median (range) were 7.8% 
(6.2%–12.1%), 1.9% (1.5%–7.4%), 3.4% (2.6%–8.5%), 1.9% (0.8%–20.0%), 2.4% (2.1%–8.0%), 
1.9% (1.5%–3.4%) for the PMN, PBMC, T, B, NK and monocyte, respectively. The outliers in 
(E) represent values from donor 1 B cells duplicates and the outliers in (F) represent values from 
donor 3 PMN duplicates and donor 1 B cells duplicates. 
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Figure 2.9 Box-whisker plot comparing CS average chain length from leukocytes 
from 4 donors 
The average chain lengths were calculated from the total CS saccharide ion 
abundance/(GalNAcSO3 and saturated disaccharides ion abundances). The median (ranges) were 
9 (7–13), 37 (12–39), 24 (10–29), 43 (10–29), 35 (5–74), and 31 (11–42) for the PMN, PBMC, T, 
B, NK and monocyte, respectively. The box-whisker plot notation was the same as given in the 
Figure 2.2 legend. 
 
2.3.5 Leukocyte CS is primarily 4-O-sulfated  
 All leukocyte populations including PMN and PBMC (B cells, T cells, NK cells, 
and monocytes) have > 70% of monosulfated disaccharide units (D0a4/D0a6) (Figure 
2.8). In order to determine the position of sulfate group (4O-or 6O-) for these 
monosulfated disaccharides, we used tandem mass spectrometry. As shown in Figure 
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2.10A and 10B, the Y1 ion (m/z 300.0484) is diagnostic for D0a4 while the Z1 ion 
(m/z 282.0362) is diagnostic for D0a6. We established a standard curve regarding the 
relationship between relative abundance of ion Y1 relative concentration of D0a4 (Figure 
2.10C).  As shown in Figure 2.10D, all leukocytes contained predominantly D0a4 with 
very low levels of D0a6, which is consistent with previous reports (133,134). Thus, the 
primary CS chain characteristics that vary among leukocytes are length and number of 
chains. 
 
Figure 2.10 Determination of abundances of 4O- versus 6O-sulfated disaccharide 
abundances using tandem MS 
(A) Tandem mass spectrometry for D0a4 standard showing Y1 ion as a diagnostic ion. (B) 
Tandem mass spectrometry for D0a6 standard with Z1 ion as a diagnostic ion. (C) The linear 
relationship between D0a4/(D0a4+D0a6) and Y1/(Y1+Z1). (D) Table showing the D0a4 relative 
abundances for human leukocyte cell populations. 
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2.4 Discussions and conclusions  
2.4.1 Cell type specific expression of CS and HS 
 In order to correlate GAG expression and disease conditions, it is necessary to 
understand the expression of GAGs in the context of normal human genetic variability. 
Previous studies have demonstrated organ tissue-specific GAG expression patterns 
(30,31). In addition, a highly sulfated non-reducing terminal domain seems to be 
common to HS from different organs (123). Much less information is known regarding 
comparative GAG structural expression on specific cell types. Further, the extent to 
which GAG expression varies for a given cell type among different individuals has not 
been established. 
 Blood cell types derive from either myeloid lineage (red blood cells, monocytes, 
PMNs, dendritic cells) or lymphoid lineage (B cells, T cells and NK cells), both of which 
arise from hematopoietic stem cell differentiation. Our data showed that HS and CS were 
expressed in leukocyte cell type-specific patterns characterized by consistent trends 
among four donors. Among the four donors, the trends showed that lymphocytes, 
especially T and B cells, express higher levels of HS and with higher overall sulfation 
levels than monocytes or PMN; however, monocytes and PMNs express much more CS 
than lymphocytes. We find that PMNs display shorter average CS chain length than that 
of monocytes, while the two cell types have similar CS abundances. We conclude that 
there are more CS chains attached to serine residues of core proteins of PMNs relative to 
monocytes. While our experiments did not differentiate between intracellular and cell 
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surface locations, these results are consistent with differences in CS expression related to 
protein binding on the surfaces of PMN versus monocytes (142,143). 
 Our results show that all leukocytes express more CS than HS, a trend most 
pronounced for PMNs and monocytes. Viewed according to similarity of GAG structure, 
monocytes and PMNs versus lymphocytes constitute two groups related by patterns of 
HS and CS total abundances. The GAG expression difference between myeloid lineages 
(PMNs and monocytes from our study) and lymphoid lineage (B cells, T cells and NK 
cells) may correlate with the hematopoietic stem cell differentiation process. Detailed 
studies of mRNAs level of respective enzymes in precursor stem cells are necessary in 
order to reach solid conclusions. 
 Our results shed new light on GAG expression in peripheral blood cells. Such 
expression has traditionally been regarded as homotypic (134). Our data show, however, 
that CS chain length varies among leukocytes and that PMNs have elevated levels of 
disulfated disaccharide units with respect to other leukocytes. All leukocytes expressed 
highly sulfated HS chains, irrespective of their relative cytotoxicities. We were not able 
to determine HS relative chain lengths from these data due to low abundance. Our results 
demonstrate the need to isolate intracellular versus cell surface GAGs in order to provide 
a better understanding of GAG structure and its possible roles in leukocyte biology. 
2.4.2 Serglycin, the most abundant proteoglycan in leukocytes  
 Fadnes et al. in their recent paper (152) demonstrated that the intracellular 
proteoglycan serglycin mRNA is dominant in lymphocytes including CD4+ T cells, 
CD8+ T cells, B cells and NK cells. They also showed that no syndecan or glypican 
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mRNA was detected in lymphocytes, except for syndecan-4 in CD4+ T cells and CD8+ T 
cells. Syndecan-1 has been reported from ELISA results to be absent from hematopoietic 
lineage cells other than B cells (147). Because the levels of syndecan-1 in B cells are low, 
we conclude that the majority of HS and CS detected in our study are associated with 
serglycin and/or intracellular granules. Serglycin is found in intracellular granules of mast 
cells, macrophages, neutrophils, cytotoxic T cells and endothelial cells (154). Human 
serglycin has eight potential GAG attachment sites that are primarily CS except in 
connective mast cells where heparin is attached to the core protein. It is well established 
that heparin in connective mast cells participates in storage of granule proteases and in 
tryptase activation (155-157). Previous studies also show that serglycin is required for 
elastase storage in neutrophils and granzyme B storage in CTLs (139); however, the 
mechanisms involved in such enzyme storage are not yet clear. Therefore, it is reasonable 
to suspect that serglycin in neutrophils and CTLs might express highly sulfated heparin-
like GAGs to promote binding of positively charged elastase and granzyme B by 
electrostatic interactions. To date, there have been no studies showing the detailed HS 
structures/compositions in leukocytes needed to develop an understanding of the storage 
mechanism. As shown in our study, HS expression is low in leukocytes and therefore it is 
difficult to get sufficient information about the HS structure using traditional 
biochemistry tools. 
 The SEC-MS methods we used show structural details of HS extracted from 
leukocytes. To our surprise, all the cell leukocytes populations, especially T cells, contain 
levels of D2S6 (around 30%) considerably higher than observed for organ derived HS 
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other than from intestinal mucosa (31). Therefore, our study supports that such heparin-
like HS plays a common role in leukocytes. This may include intracellular protease 
transport and storage as well as cell-surface binding of proteases. In order to support this 
theory, we plan to isolate intracellular and cell-surface associated GAGs in order to 
determine the patterns of expression of heparin-like HS. In addition, highly sulfated HS 
may have other biological functions that are so far not clear. 
 PBMC compositions in normal adults are approximately 60% T cells, 15% 
monocytes/macrophages, 10% B cells and 15% NK cells. Thus, the levels of GAG 
observed in PBMC reflect a combination of the levels in T cells, B cells, NK cells and 
monocytes. We observed, however, that the level of HS in PBMC was higher than for T 
cells, B cells, NK cells and monocytes. The level of CS in PBMC was close to that of 
monocytes but much higher than for T cells, B cells and NK cells. We speculate that 
either: 1) a population of cells not isolated from PBMC contained a high level of HS and 
CS; or 2) the low levels of HS and CS in lymphocytes resulted from a serglycin secretion 
process that occurred during cell isolation (152). 
2.4.3 GAG expression and cell activation  
 Our study focused on comparative glycomics of leukocyte GAGs from four 
healthy donors. We note that biosynthesis shifts from CS-4 (D0a4) to a mixture of CS-4 
(D0a4) and CS-E (D0a10/D2a6/D2a4) when monocytes differentiate into macrophages. 
In addition, the expression of CS-E is further increased when macrophages are activated 
after differentiation (158,159). From our data, PMN from donors 2 and 4 showed higher 
abundances of CS-E (D0a10/D2a6/D2a4) than other cell populations. We therefore 
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suspect that the increase in CS-E in donor 2 and donor 4 may indicate PMN activation; 
PMN are easily activated during isolation and the degree to which this occurs is likely to 
be donor-specific. Further controlled studies on GAG expression during PMN activation 
are needed to verify these observations. 
 Cell surface HS in activated CD+4 T cells are also involved in entry of human T 
cell leukemia virus type 1 (HTLV-1) (160). In addition, sydecans-1 and -2, bearing short 
heparin-like chains, are required for HTLV-1 entry into activated T cells (161). Although 
among syndecans, only syndecan-4 mRNA levels have been detected in inactivated T 
cells, both syndecan-4 and sydecan-1 mRNA levels increase during T cell activation 
(152). Therefore it is of interest to investigate HS structural changes in sydecan-4 and 
sydecan-1 proteoglycans after T cell activation. 
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Chapter 3. Mass Spectral Profiling of Glycosaminoglycans from Histological Tissue 
Surfaces 
3.1 Introduction  
3.1.1 Glycosaminoglycans are expressed in a spatially and temporally regulated 
manner  
 Glycosaminoglycans (GAGs) are a family of linear sulfated polysaccharides 
found in cellular granules on cell surfaces and in extracellular matrices of animal cells. 
Among GAGs, heparin, heparan sulfate (HS), chondroitin sulfate (CS), and dermatan 
sulfate (DS) bind many families of growth factors and growth factor receptors (162,163). 
They serve as co-receptors for growth factor-growth factor receptor interactions and bind 
growth factors and other proteins in the extracellular matrix. Such GAG-protein 
interactions are necessary for embryogenesis and the functioning of every adult 
physiological system (164). GAG chains are heterogeneous, and their structures vary 
according to tissue type (30). While there is general appreciation regarding the regulated 
nature of GAG chain structure, it has not been possible to produce sufficient structural 
information to understand their roles in disease states including cancers. 
 GAGs are expressed in a spatially and temporally regulated manner (165). Thus, 
the structure and abundance of GAG chains varies according to the cell type, 
developmental state, and regulatory signals received from the extracellular matrix. 
Understanding of the roles of GAGs in physiology therefore depends on the ability to 
determine the structures and abundances of GAGs from small quantities of tissue. 
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 Others and we have studied the expression of GAGs in tissue related to a variety 
of disease states (38,153,166-171). These studies leveraged the ability to extract GAGs 
from comparatively small quantities of tissue (31,172). Thus, it was possible to compare 
structures of chondroitin/dermatan sulfate in human squamous cell carcinoma biopsies 
(153). It was clear from these studies, however, that the heterogeneity of the biopsy tissue 
limited the ability to determine the structures of GAGs expressed by cancer cells versus 
those from surrounding non-cancerous cells. We therefore sought to develop methods to 
analyze GAGs from smaller tissue quantities. 
3.1.2 Analysis of glycosaminoglycans from histological tissue sections  
 MALDI-based imaging mass spectrometry (IMS) has advanced to the point that 
protein and lipid profiles can be obtained on tissue spots less than 25 microns (173). 
Glycoconjugate glycans, however, are not typically observed in MALDI IMS 
experiments. Glycans dissociate under typical vacuum MALDI conditions, a fact that is 
likely to limit the ability to perform tissue-based imaging and profiling experiments. In 
addition, ionization of glycans, as hydrophilic molecules, is easily suppressed by more 
hydrophobic proteins and lipids present in the tissue. The analysis of N-glycans 
enzymatically released from tissue surfaces has been accomplished by permethylation 
prior to MALDI-TOF mass spectrometry (69). These results demonstrate the validity of 
derivatization to improve the stability and ionization responses of the N-glycans. In order 
to analyze GAGs as permethylated derivatives, it is necessary to use a multistep 
derivatization process in which sulfate groups are replaced by acetate groups prior to MS 
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analysis (174). We have chosen to analyze GAGs enzymatically released from tissue 
surfaces in native form in order to keep the analytical workflow as simple as possible. 
 Analysis of GAGs from tissue sections was first reported for hyaluronan and 
chondroitin sulfate and was carried out using formalin fixed paraffin embedded tissue 
that had been subsequently de-waxed and re-hydrated before applying GAG-degrading 
enzymes (175,176). The released GAG disaccharides were then detected using reversed 
phase ion pairing chromatography with post-column fluorescence derivatization and 
detection. Tissue may also be embedded in optimal cutting temperature polymer, 
sectioned using a cryostat, fixed with methanol and dried on a glass slide. 
Chondroitin/dermatan sulfate GAGs have been analyzed from tumor tissue prepared in 
this way on glass slides by adding enzyme digestion solution to the dried tissue. The 
digest was analyzed by reversed phase ion pairing LC/MS (177). Corneal keratin sulfate 
(KS) GAGs were analyzed from fresh frozen tissue sections by applying a ring around 
tissue to be analyzed using a hydrophobic pen (178,179) followed by direct electrospray 
mass spectrometric analysis of mono- and di-sulfated disaccharide products. 
 Given the feasibility of ESI mass spectral analysis of GAGs from tissue surfaces, 
we sought to develop methods appropriate for quantitative studies. A reproducible and 
quantitative method is necessary in order to compare the structures of GAGs expressed in 
normal versus disease tissue. We were concerned that surface effects would limit the 
reproducibility of direct MS analysis of enzyme digest solutions. Size exclusion 
chromatography (SEC)-MS has proven to be extremely useful for quantitative 
comparison of GAG disaccharide profiles among tissue and cell types (31,123,153,180-
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185). The method is very robust and removes components from the tissue that interfere 
with ionization of the disaccharide analytes. Therefore, we compared direct nano-
ESI versus SEC-MS methods of quantification of GAGs released from tissue surfaces. 
The results demonstrated that both CS/DS and HS GAGs may be analyzed reproducibly 
from slides prepared from frozen tissue. The method was applied to analysis of HS from 
human glioma biopsies. 
3.2 Experimental Section 
3.2.1 Materials  
 Frozen bovine cortex, brain stem and cerebellum slides, which were cut at a 
thickness of 15 μm, and the tissue blocks from which the slides were prepared were 
purchased from Zyagen (San Diego, CA). Each slide contained two sections. Frozen 
diffuse astrocytoma (WHO grade II) slides and glioblastoma (GBM, WHO grade IV) 
slides, which were cut at a thickness of 10 μm, were prepared at University of California 
San Francisco. Each slide contains one section. Heparin lyase I was purchased from New 
England Biolabs (Andover, MA) and heparin lyases II and III were generous gifts from 
Prof. Jian Liu (UNC Eshelman School of Pharmacy, USA). Heparan sulfate sodium salt 
from porcine intestinal mucosa (HSPIM) was purchased from Celsus Laboratories 
(Cincinnati, OH). Phosphate buffered saline (PBS), protease from Streptomyces griseus, 
Triton X-100,benzonase, and DEAE-Sepharose were purchased from Sigma-Aldrich (St. 
Louis, MO). 10 ml poly- prep chromatography columns were from Bio-Rad (Hercules, 
CA). Disposable PD-10 desalting columns were obtained from GE Healthcare Life 
Sciences (Piscataway, NJ). 
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3.2.2 Frozen tissue slides processing before enzymatic digestion  
 Frozen tissue slides were washed using chloroform:methanol solution (v/v=7:3) 
for 10 min, twice, to remove lipids. Isopropanol:distilled water solution (v/v=1:1) was 
then used to wash the slides for 10 min, twice. A 20 mM ammonium bicarbonate solution 
(pH adjusted to 9.0) was applied to dissolve acidic molecules on the tissue surfaces for 10 
min, twice. The tissue slides were then washed using distilled water for 10 min, three 
times. The slides were then allowed to dry in air. 
3.2.3 Enzyme digestions for HS at tissue surfaces  
 Three digestion spots (with the size of 5mm × 5mm) were chosen in each frozen 
bovine cortex, brain stem and cerebellum frozen histological section. Ten serial sections 
were used for each sample to verify the reproducibility of the method and the spatial 
positions of digestion spots were carefully coordinated. 
 Fresh frozen histological slides were prepared for three diffuse astrocytomas 
biopsies samples and five GBM biopsies samples were prepared. One or two digestion 
spots were chosen from each frozen section. The number of digestion spots was 
determined by the histological characteristics of the sample. Three serial sections were 
used for each sample and the spatial positions of the digestion spots were also carefully 
coordinated. The abundances of disaccharides were normalized to 1mm2 digestion spot 
size. 
 The tissue slides were put in a sealed box during digestion to maintain an 
atmosphere saturated with water vapor at 37 °C. A 5 μl volume of enzyme solution I, 
containing 20 mU of heparin lyase I (specific for highly sulfated HS domains), 2 mU of 
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heparin lyase III (specific for HS domains with a low degree of sulfation) and 2 mU of 
heparin lyase II (cleaves all HS domains) in the presence of 10 mM Tris/HCl buffer 
pH7.4 and 2 mM CaCl2, was added to the defined digestion spot at 37 °C for 45 min. In 
order to keep the digestion spot wet, a 5 μl volume distilled water was then added and the 
digestion was allowed to proceed for another 45 min at 37 °C. The cycle of addition of 
enzyme solution I and distilled water was then repeated 3 more times. Finally, 5 μl 
enzyme solution II containing only 20 mU of heparin lyase I, 2 mU of heparin lyase II 
and 2 mU of heparin lyase III was added for 45 min at 37 °C. The digested products were 
aspirated by pipetting 6 μl 0.3% ammonium hydroxide solution into each digestion spots. 
Aspiration steps were repeated for another 5 times and the extraction volumes were 
combined. The solutions extracted from each spot were dried using a vacuum 
concentrator and dissolved in 10 μl distilled water.  
3.2.4 GAG extraction from tissue blocks and enzymatic digestion for GAG 
 The tissue slides were put in a sealed box during digestion to maintain an Fresh 
bovine cortex, brain stem and cerebellum frozen tissue blocks were firstly cut into three 
small pieces of approximately 0.3cm*0.3cm*0.3cm in dimension and lyophilized at 
ambient temperature for two days. Dry weight of tissue blocks was measured. A 1 ml 
volume of phosphate buffered saline (PBS) lysis buffer containing 1 mg protease from 
Streptomyces griseus and 1% Triton X-100 was added to the cortex, brain stem and 
cerebellum dry tissues in parallel, and the solutions were mixed end-over-end overnight 
at 55°C. A 0.5 mg quantity of protease was then added to the solutions and the samples 
were mixed end-over-end overnight at 55°C. Protease was heat inactivated at 100°C for 
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10 min, followed by adding 10 µl 200 mM MgCl2 and 300 mU of benzonase. The 
samples were incubated at 37°C for 3 hours and then adjusted to 0.5 M NaOH. The 
samples were then mixed end-over-end at 4°C overnight and pH was adjusted to 5.0 
using acetic acid. The samples were centrifuged at 20,000x g for 5 min and the 
supernatants were transferred to clean tubes. The supernatants were diluted with 2-3 ml 
distilled water and then applied to a DEAE-Sepharose column. The DEAE Sepharose 
columns were prepared by adding 1.4 ml DEAE-Sepharose to a 10 ml polyprep 
chromatography column. GAGs were eluted with 2.5 ml of 1 M NaCl, 20 mM NaOAc 
pH 6.0, and the eluates were further desalted using PD-10 columns. Finally, each desalted 
solution was divided into six aliquots and dried overnight in a vacuum concentrator. The 
absolute abundances of disaccharides and total HS abundances have been normalized to 1 
mg dry tissue weight. 
 Enzyme digestions for heparan sulfate extracted from tissue blocks. One aliquot 
of GAG was digested with 100 mU of heparin lyase I, 10 mU of heparin lyase II, and 10 
mU of heparin lyase III in a final volume of 30 µl containing 20 mM Tris/HCl buffer pH 
7.4, in the presence of 5 mM CaCl2. The digestion was incubated at 37°C for 5 h and a 
second aliquot of the heparin lyase I, II, III mixture was added prior to overnight 
incubation at 37°C. 
3.2.5 SEC-MS analysis for GAG 
 The SEC-MS method and appearance of GAG disaccharide mass spectra 
produced has been described previously (31,56). 
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3.2.6 Direct nano-ESI mass spectrometry analysis for GAG 
 An LTQ-Orbitrap XL instrument (ThermoFisher Scientific, San Jose, California) 
coupled with a Triversa Nanomate system (Advion Biosystems, Inc., Ithaca, NY) was 
operated in negative ion mode to directly spray extracted digestion products. The 
capillary voltage was set to 1500 V. The mass spectra range for recording data was set to 
m/z 200-2000. The dry samples were dissolved in 50% methanol/50% HPLC water 
3.3 Results 
3.3.1 SEC-MS is a reliable and robust method to analyze HS released from tissue 
surfaces  
 Heparan sulfate can be digested into disaccharides using heparin lyases I, II, and 
III. Among unsaturated disaccharides, D0A0, D0S0, D0A6/D2A0 and D0S6/D2S0 are 
the four most abundant signals detected from typical HS sources. HS disaccharides 
extracted from two spots in the bovine hippocampus, cortex, cerebellum and brain stem 
slides were analyzed by both direct nano-ESI MS and SEC-MS, as shown in Figure 3.1.  
 Despite the convenience, direct nano-ESI MS produced considerably higher 
variability between the paired spots for each brain tissue than did SEC-MS. We 
concluded that molecules co-extracted from the tissue surfaces influenced the abundances 
of ions detected using direct nano-ESI MS. The use of SEC-MS appears to remove tissue 
surface molecules that interfere with direct nano-ESI MS analysis and was used for the 
remainder of the experiments here described. Representative SEC-MS total ion 
chromatograms (TICs) and extracted ion chromatograms (EICs) for HS unsaturated 
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disaccharides acquired from frozen bovine brain stem and human GBM slides are shown 
in Figure 3.2.  
 
Figure 3.1 Comparison of analysis methods for determining the relative ion 
abundances of HS disaccharides released from frozen brain tissue sections 
SEC-MS (A) and direct nano-ESI MS (B). Bovine hippocampus, cortex, brain stem and 
cerebellum tissue sections were digested using heparin lyases. The digested HS disaccharides 
were extracted and the extraction solutions divided into two equal aliquots prior to analysis. 
 
3.3.2 Recovery of HS disaccharides from tissue surfaces  
 In order to determine the efficiency of recovery of HS from the tissue surfaces, 
we digested HS from tissue surfaces using heparin lyases and extracted the disaccharides. 
We then verified that no additional disaccharides could be extracted after additional 
digestion using lyases. Next, we deposited 0.75 μg HSPIM onto the tissue surfaces where 
HS had been digested and extracted previously and used the same conditions described in 
the experimental procedures to exhaustively digest 0.75 μg HSPIM. Figure 3.3 compares  
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Figure 3.2 Representative total ion chromatograms (TICs) and extracted ion 
chromatograms (EICs) for HS unsaturated disaccharides from fresh frozen 
histology slides 
Bovine brain stem (A-E) and human glioblastoma (F-J). The D2A6 and D2S6 disaccharides from 
tissue sections were not detected. Two peaks for D0S6/D2S0 were detected because of in-source 
loss of SO3. The loss of SO3 was corrected for the quantification as described (31). 
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the absolute (A) and relative (B) abundances for five unsaturated HS disaccharides 
digested in solution versus on the frozen bovine cortex tissue slides. The coefficients of 
variation (CV) for the absolute and relative abundances from three independent 
experiments were less than 5% for all disaccharides except for the lowest in abundance 
(D2A6), indicating extraction step is consistent among different spots. The recovery for 
each digested HS disaccharide from tissue surfaces was about 90%, as shown in Figure 
3.3A. In addition, the differences of the relative abundance for the five most abundant 
disaccharides were 1.3% or less, as shown in Figure 3.3B. Digestion of 0.75 ug HSPIM 
produces approximately 50 times more disaccharides than typically present on the 
surfaces of tissue slides. Therefore, the enzymatic digestion protocol is more than 
sufficient to digest all HS present on histological slides. We also deposited 2.5, 5, and 10 
pmol of HS disaccharide standards, respectively, onto different tissue spots. These 
quantities approximate those typically found on histological slide surfaces. Figure 3.4 
shows that the extraction efficiencies for HS disaccharides standards are over 90%, 
confirming the reliability of extraction step. In summary, the recovery of digested 
disaccharides and disaccharides standards from tissue surface is acceptable and consistent 
among different spots. 
3.3.3 Method reproducibility and spatial variability for bovine brain stem, cortex, 
and cerebellum 
 We conducted the following experiment to demonstrate that instrument sensitivity 
was appropriate for analysis of HS from fresh frozen tissue slides. As shown in the Figure 
3.5, 2.5 pmol HS standards containing D0A0, D0S0, D0A6, D0S6, D2A6 and D2S6 gave  
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Figure 3.3 Comparison of the recovery of HSPIM disaccharides digested on bovine 
brain stem tissue surface versus in solution 
(A) Absolute disaccharides ion abundances; (B) relative disaccharides ion abundances. The 
height of each bar is the mean value of three independent experiments. The error bars represent 
the standard error. 
 
 
Figure 3.4 The efficiency of extraction of HS disaccharides standards extraction 
from tissue surfaces 
Quantities of 2.5, 5 and 10 pmol each of HS disaccharide mixtures containing D0A0, D0S0, 
D0A6, D0S6, D2A6 and D2S6 were applied onto different spots on the frozen bovine cortex 
slides. Over 90% recovery (with CV values less than 6%) for each disaccharide was observed. 
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acceptable EIC peaks. The signal to noise ratio (S/N) for each disaccharide monoisotopic 
peak was 6 or greater and the coefficient of variation less than 6%. Because the 
abundances of D0A0, D0S0 and D0S6/D2S0 ions observed from bovine brain, human 
astrocytomas and GBM slides correspond to greater than 2.5 pmol and that for 
D0A6/D2A0 to 2 pmol, we concluded that the instrument sensitivity was adequate. 
 
Figure 3.5 EICs for 2.5 pmol HS D0A0, D0S0, D0A6, D0S6, D2A6 and D2S6 
standards 
Signal-to-noise ratio (S/N) for each disaccharide was 6 or greater. 
 
 In order to demonstrate the reproducibility of our method, we used 10 serial 
frozen sections from brain stem, cortex and cerebellum from a single bovine brain. A set 
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of three spots was selected for each tissue section, the position of which was reproduced 
in each serial section. The absolute and relative HS disaccharide abundances released 
from bovine brain stem slides are shown in Figure 3.6A and Figure 3.6B. Statistical 
analysis of variance (ANOVA) tests were applied to demonstrate the reproducibility with 
respect to the three spots on each tissue slide. As shown in Figure 3B, p values for 
disaccharide relative abundances greater than 5% were not significant among the three 
spots. With regard to the relative abundances, CV values for D0A0 and D0S0 are 
approximately 5% and those for D0A6/D2A0 and D0S6/D2S0 approximately 12%. We 
therefore concluded that HS disaccharide composition was relatively homogenous in 
bovine brain stem. The CV values for the absolute abundances of D0A0, D0S0, 
D0A6/D2A0, and D0S6/D2S0 from ten serial sections were approximately 15% for each 
of the three spots. Since the CV value for the recovery of HSPIM standards is around 5%, 
the observed 15% CV for ten serial sections is not caused by variation in HS recovery 
from the tissue surfaces. This indicates that the CV value reflects variation in the amount 
of HS present in the series of bovine brain stem sections. These data also show that the 
HS quantity present among the three digestion spots varies significantly and is likely to 
due to spatial differences in tissue morphology. We then compared the abundances of 
disaccharides extracted from the tissue block from which slides were prepared versus 
digestion from tissue slides (Figure 3.7). The relative disaccharides abundances showed a 
3% difference between mean value of tissue block and tissue surface for D0A0 and 
D0S0, 1% for D0A6/D2A0 and 1.7% for D0S6/D2S0. This confirms the reliability of our 
method. 
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Figure 3.6 Ion abundances of HS disaccharides from bovine brain stem tissue slides 
corresponding to three spots, each of which was analyzed from 10 serial sections 
(A) Absolute disaccharide ion abundances; (B) relative disaccharides ion abundances; ***, p 
value< 0.01, high significance; **, 0.01 < p value < 0.05, medium significance. 
 
 
Figure 3.7 Comparison of the relative disaccharides abundances between HS 
digested on the surfaces of bovine brain stem tissue slides and that extracted from 
the tissue block from which the slides were prepared 
A 3% difference between mean value of tissue block and tissue surface was observed for D0A0 
and D0S0, 1% for D0A6/D2A0 and 1.7% for D0S6/D2S0. 
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 We observed similar results for the same experiment using slides from bovine 
cortex, as shown in Figure 3.8A and Figure 3.8B. Statistical analysis of variance 
(ANOVA) of the data showed p values (shown in the figure) that indicated significant 
differences among three digestions spots in terms of the absolute disaccharides 
abundances. ANOVA calculations showed that the relative abundances had p values > 
0.05, indicating that they were not significantly different. The CV values for the absolute 
abundances of D0A0, D0S0, D0A6/D2A0, and D0S6/D2S0 from ten serial sections were 
approximately 15%. The CV values for the relative abundances were D0A0 (5%), D0S0 
(5%), D0A6/D2A0 (8%), and D0S6/D2S0 (12%). In summary, the slight differences 
among absolute disaccharide abundances among serial sections were also detected in 
bovine cortex, which is acceptable for biological samples. The data also demonstrated 
that statistically significant differences in HS absolute abundances were present among 
the three digestion spots on each tissue slide. In addition, a 2.5% difference between 
mean relative abundance values for tissue block versus tissue surface was observed for 
D0A0 and D0S0 and 0.5% for D0A6/D2A0 (Figure 3.9). 
 As shown in Figure 3.10A, ANOVA calculations showed p values > 0.05, 
indicating no significant differences in absolute disaccharide abundances among three 
spots digested on bovine cerebellum tissue slides. These slides produced high CV values 
of approximately 40%. H&E staining was applied to see the morphological 
characteristics of cerebellum continuous slides (Figure 3.11). These data show that 
variability of cerebellum tissue morphology among serial sections, give rise to the 
observed high CV values. As with the other bovine brain tissues, p values for relative  
  
69 
 
Figure 3.8 Ion abundances of HS disaccharides from bovine brain cortex tissue 
slides corresponding to three spots, each of which was analyzed from 10 serial 
sections 
(A) Absolute disaccharides ion abundances; (B) relative disaccharides ion abundances***, p 
value< 0.01, high significance; **, 0.01 < p value < 0.05, medium significance. 
 
 
Figure 3.9 Comparison of the relative disaccharides abundances between HS 
digested on the surfaces of bovine brain cortex tissue slides and that extracted from 
the tissue block from which the slides were prepared 
A 2.5% difference between mean value of tissue block and tissue surface was observed for D0A0 
and D0S0 and 0.5% for D0A6/D2A0. 
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disaccharide abundances were > 0.05 for three spots (Figure 3.10B). The CV values for 
the relative disaccharide abundances of D0A0 and D0S0 were approximately 5%, and 
those for D0A6/D2A0 and D0S6/D2S0 approximately 10%. A 1% difference between 
mean value for disaccharides extracted from tissue block versus tissue surface was 
observed for D0A0 and 3% for D0S0 and D0A6/D2A0 (Figure 3.12).  
 
Figure 3.10 Ion abundances of HS disaccharides from bovine brain cerebellum 
tissue slides corresponding to three spots, each of which was analyzed from 10 serial 
sections 
(A) Absolute disaccharides ion abundances; (B) relative disaccharides ion abundances of 
disaccharides; ***, p value< 0.01, high significance; **, 0.01 < p value < 0.05, medium 
significance. 
 
3.3.4 Application to human glioma samples  
 Astrocytomas and GBMs represent different stages of human gliomas. We 
applied our method to profile HS in 3 astrocytoma samples and 4 GBM samples. It is  
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Figure 3.11 Representative images of H&E stained sections of frozen bovine 
brainstem (A, B), bovine cortex (C), bovine cerebellum (D), human WHO grade II 
astrocytoma (E), and human WHO grade IV astrocytoma (F) 
In the brainstem, region 2 (A) contained abundant neurons (arrowheads) while region 3 (B) did 
not. Scale bar 100 µm. 
 
 
Figure 3.12 Comparison of the relative disaccharides abundances between HS 
digested on the surfaces of bovine brain cerebellum tissue slides and that extracted 
from the tissue block from which the slides were prepared 
A 1% difference between mean value of tissue block and tissue surface was observed for D0A0 
and 3% for D0S0 and D0A6/D2A0. The error bars correspond to the standard error. 
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Figure 3.13 The ion abundances of HS disaccharides released from human glioma 
slides 
A set of three serial slides was used for the analysis of each individual. Astrocytoma (WHO grade 
II) samples from 3 individuals and GBM (WHO grade IV) samples from 4 individuals were 
obtained from biopsies. The mean value obtained from the set of individuals is shown. (A) 
Absolute disaccharides ion abundances; (B) relative disaccharides ion abundances. T-tests with 
two tailing were used for these data; ***, p value< 0.01, high significance; **, 0.01 < p value < 
0.05, medium significance. 
 
 
Figure 3.14 The stability of SEC-MS instrument during data acquisition period.  
External standard mixtures containing D0A0, D0S0, D0A6/D2A0, D0S6/D2S0 and D2A6 were 
used to monitor instrument stability over 15 days. The coefficient of variation (CV) values for the 
absolute abundances of D0A0, D0S0, D0A6/D2A0, D0S6/D2S0 and D2A6 were less than 5%. 
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interesting to note that ANOVA calculations showed that absolute abundances for HS 
disaccharides were significantly higher in GBM than astrocytomas, as shown in Figure 
3.13A. The CVs for the absolute disaccharide abundances were within 15% for each 
individual. In addition, ANOVA calculations showed that statistically significant 
increases in relative abundances of D0A0% and D0S0% and decreases in D0A6/D2A0% 
and D0S6/D2S0% in GBMs compared with astrocytomas, indicating lower sulfation 
level in GBMs. The CV values for the relative abundances of D0A0 and D0S0 were 
approximately 5% and those for D0A6/D2A0 and D0S6/D2S0 approximately 10% for 
each individual. We collected data demonstrating that the SEC-MS instrument was stable 
(with CV values for the absolute abundances of D0A0, D0S0, D0A6/D2A0, D0S6/D2S0 
and D2A6 were less than 5%) over the duration of the time during which the data were 
acquired Figure 3.14. We therefore conclude that there are significant differences in HS 
disaccharide abundances between the set of GBM and astrocytoma samples analyzed in 
this work. 
3.4 Discussions and conclusions 
3.4.1 Tissue surface digestion to limit tissue heterogeneity  
 Profiling HS from histological tissue surfaces by SEC-MS provides a sensitive 
and feasible method to understand HS structure and distribution than traditional 
extraction HS from whole tissue and provides a means of limiting tissue heterogeneity. 
The traditional method for extraction of HS from wet tissue requires several days to 
complete and a minimum of 10 mg wet tissue weight. The on-slide digestion we show 
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can be accomplished by digesting a tissue slide corresponding to a fraction of a milligram 
tissue with no prior extraction necessary. 
 There is increasing evidences showing involvement of proteoglycans in cancer 
development, metastasis and other pathogenic processes in vivo and in vitro. The 
majority of these studies focus on core protein expression levels due to lack of 
appropriate methods for the GAG chains. To better understand the roles of GAGs in 
cancer development, it is important to compare the GAG quantities and structures 
between tumor and normal tissue. Considering the heterogeneity of normal tissue and the 
tumor microenvironment, we developed a profiling method for GAG applicable to the 
histological scale. Our method is reproducible and sensitive enough for studies of human 
brain gliomas. The results have the potential to shed light on the role of GAG in 
pathogenic processes. 
3.4.2 HILIC-MS for rapid and sensitive analysis of tissue surface extracted GAG 
 In summary, the results shown here demonstrate the feasibility of recovering 
GAGs from histological surfaces. GAG abundances differ according to location, 
indicating the importance of achieving reproducible analysis. We demonstrate that SEC-
MS enables considerably more reproducible analysis than does direct ESI-MS of enzyme 
digestion solutions, presumably due to the removal of molecules that interfere with 
analyte ionization. SEC-MS is slow, however, indicating that more rapid LC-MS 
methods are needed. We recently published a HILIC-MS method for disaccharide 
analysis (67) and are in the process of optimizing it for rapid and sensitive analysis of 
tissue GAGs at reduced chromatography scale.  
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Chapter 4. Integrated Omics for Tissue Microarrys with A High-throughput Mass 
Spectrometric Profiling Method  
4.1 Introduction  
4.1.1 Intra-tumor heterogeneity 
 Tumor heterogeneity describes the difference between tumors of the same type in 
different patients as well as between cancer microenvironment within a tumor, which is 
recognized as intra-tumor heterogeneity. Human cancers display varying degrees of intra-
tumor heterogeneity with respect to cellular morphology (as shown in the Figure 4.1), 
cellular metabolism, genetic alterations, motility, secretome, angiogenic potential, drug 
response, immune response, senescence, signaling pathway, and proliferation ability 
(186-193). Intra-tumor heterogeneity complicates accurate clinical cancer diagnosis and 
prognosis, effective cancer treatment and personalized medicine (194-196). Therefore, a 
better understanding about the composition of tumor and the alterations in the cell 
populations of cancer microenvironment during tumorigenesis and treatment will 
improve cancer diagnosis and treatment. 
 One effective experimental method to infer the intra-tumor heterogeneity is to 
carry out in situ analysis of tissue histological section, thereby preserving tissue 
morphology (188). We therefore approached used formalin fixed paraffin embedded 
(FFPE) histological tissue sections, which are routine for diagnostic pathology. In so 
doing we gained access to large cohorts of FFPE tumor biospecimens available.  
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Figure 4.1 Tumor heterogeneity shown at two adjacent tumor regions, adapted from 
reference (197) 
 
4.1.2 Tissue microarray technology for high-throughput molecular profiling of 
tumor samples in situ  
 Tissue microarray (TMA) technology was developed as a high-throughput 
molecular biology technique for researchers that allows assessment of the disease state on 
hundreds of biospecimens on a single slide (198,199).  The TMA platform enables 
pathologists to perform large-scale analyses using fluorescence in situ hybridization 
(FISH), RNA in situ hybridization (ISH) and immunohistochemistry in higher throughput 
and lower costs than with traditional methods. As shown in the Figure 4.2, TMAs are 
constructed by punching cylindrical tissue cores from selected regions of paraffin blocks 
from different tumors and re-embedding these into a single recipient paraffin block at 
defined array coordinates. Using a microtome, tissue sections are cut from the recipient 
High grade carcinoma 
Well-formed elongated tubules; 
Without significant nuclear pleomorphism 
Low grade carcinoma 
Cribriform growth pattern  
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block to generate hundreds of serial tissue microarray slides. The current maximum 
number of tissue cores on a standard glass microscope slide is about 1000 (200). 
Therefore, TMAs facilitate the study of prognostic and diagnostic makers in large 
numbers of biospecimens to elucidate the fundamental molecular mechanisms in disease 
states. Since the typical size for TMA cores (less than 2mm diameter) is much smaller 
than bulk tissues, significantly increase the spatial resolution and reduce intra-tumor 
heterogeneity (197).  
 
Figure 4.2 Tissue microarray construction process, adapted from reference (200)  
 
4.1.3 High-throughput mass spectral profiling experimental workflow for integrated 
glycomics and proteomics from tissue surface digestion 
 Recently, high-throughput methods for proteomic analysis and N-glycan profiling 
of FFPE tissue microarrays with MALDI imaging have been developed (201,202).  Such 
MALDI imaging is useful for detecting the biodistribution of N-glycans and peptides 
IHC,	FISH	and	ISH	
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with limited analytical depth. One problem with this approach is that the signal responses 
for glycans and peptides vary resulting from the tissue surface physicochemical 
properties. Our lab developed a tissue surface profiling workflow to identify peptides and 
quantify glycans and peptides at maximum analytical depth using ESI-LC-MS/MS 
(55,68).  In order to improve the throughput and increase spatial resolution, we developed 
a high-throughput mass spectral profiling workflow to integrate glycomics, 
glycoproteomics, and proteomics from TMA tissue surfaces (Figure 4.3). Sequential 
addition of heparin lyases, chondroitinase ABC, and trypsin were applied onto the TMA 
tissue surface. The digested molecules were extracted and subjected to LC-MS/MS 
analysis.   
 
Figure 4.3 High-throughput mass spectral profiling experimental workflow for 
HS/CS/proteins from tissue surface digestion 
 
HS dp2s 
nanoHILIC-LC MS/MS using QE+ 
CS dp2s 
HILIC-LC MS/MS using Orbitrap XL 
TMA section 
A. Automated application of enzymes to the surface  
with a chemical inkjet printer (CHIP-1000) 
 (heparin lyases, chondroitinase ABC, and trypsin sequentially)  
B. Digest 
C. Automated extraction of digested products 
Peptides (glycopeptides) 
nanoC18-LC MS/MS using QE+ 
Label free quantification 
Liquid microjunction surface extraction 
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  As shown in the Figure 4.4, we used 1.5 mm diameter, 5 µm thick TMA cores, 
equal to 9 nL tissue volume. Within such tissue volume, we expect 0.2-1.0 μg protein, 
0.2-20 ng CS, and 0.05-0.5 ng HS.  These GAG levels are beyond the lower sensitivity 
limit of the SEC-MS in routine use in the laboratory. Therefore, we optimized a nano-
fluidic HILIC-LC-MS/MS analytical method to meet the required sensitivity 
 
Figure 4.4 HS/CS/protein expression in 1.5 mm ID, 5 μm thickness TMA core  
 
4.2 Experimental section  
4.2.1 Materials 
 Formalin fixed paraffin embedded (FFPE) tissue microarrays were purchased 
from US Biomax, Inc. (Rockville, MD). Chondroitin sulfate sodium salt from shark 
cartilage, ammonium acetate, ammonia hydroxide solution, ammonium bicarbonate, and 
chondroitinase ABC enzyme were from Sigma-Aldrich. Heparan sulfate sodium salt from 
porcine intestinal mucosa (HSPIM), heparan sulfate disaccharides, and chondroitin 
sulfate disaccharides were purchased from Celsus Laboratories (Cincinnati, OH). Heparin 
lyases I, II, and III were generous gifts from Prof. Jian Liu (UNC Eshelman School of 
Pharmacy, USA). Slide-A-Lyzer
TM
 MINI dialysis device, 2K MWCO (0.1 mL), HPLC 
grade water, formic acid, and acetonitrile (ACN) were from Thermo Fisher Scientific
TM
 
(San Jose, CA). 2.1mm*15cm HILIC Accucore
TM, 2.1mm*15cm, and 300μm*15cm 
GlycanPac AXH-1 column were generous gifts from Thermo Fisher Scientific
TM
 (San 
ID	of	each	core	is	1.5mm,	5μm	thickness	(9nL	
ssue	volume):		
0.2-1.0ug	proteins;	
0.2-20ng	CS;	
0.05-0.5ng	HS;	
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Jose, CA). A 2.1mm*15cm HLIC BEH column (1.7µm BEH HILIC resin) was pursued 
from Waters Corp (Milford, MA). Trypsin gold, mass spectrometry grade was from 
Promega Corp (Madison, WI).  
4.2.2 Automated enzyme addition into tissue surfaces with inkjet chip printer  
 A chemical inkjet chip printer (Shimadzu CHIP-1000) was used for printing 
enzymes to tissue surfaces. This device is capable of applying minimal 500 pL solutions 
to tissue surfaces. The printer scans an image of TMA slide, which enables the user to 
designate the cores to be analyzed. Next, 1 μL enzyme solution was applied to each 
designated core using a user-defined printing pattern. To insure exhaustive digestion, the 
enzyme printing process was repeated 4 times. The time interval for the repeated enzyme 
printing was 2 hours. After the 4
th
 enzyme printing, the TMA slides were incubated in a 
humidified digestion chamber at 37°C, overnight.  
 Heparin lyase enzyme solution preparation for chip printer: a mixture of 2 mU 
/μL heparin lyases I, II, and III was dialyzed against 5 mM ammonium acetate solution at 
4°C for 3 hours with Slide-A-Lyzer
TM
 MINI dialysis device, 2K MWCO (0.1 mL). After 
dialysis, 5 mM ammonium acetate is used to make 0.5mili unit/μl heparin lyases solution, 
which is ready for use.  
 Chondroitinase ABC enzyme solution preparation for chip printer: a mixture of 4 
mU/μL chondroitinase ABC was dialyzed against 5mM ammonium bicarbonate solution 
at 4°C for 3 hours with Slide-A-Lyzer
TM
 MINI dialysis device, 2K MWCO (0.1 mL). 
After dialysis, 5mM ammonium bicarbonate is used to make 1 mU/μL chondroitinase 
ABC solution for use.  
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 Trypsin enzyme solution preparation for chip printer: a bottle of trypsin enzyme 
containing 20 μg lyophilized powder was reconstituted with 200 μL 10mM ammonium 
bicarbonate solution. Therefore, 100 ng/μL trypsin solution is ready for use.  
4.2.3 Automated extraction of digested molecules from tissue surfaces with 
Nanomate robot  
 Liquid extraction surface analysis (LESA) entails automated extraction of 
compounds from tissue surface with minimized disturbance to tissue. A LESA module 
has been developed for the widely used Advion Triversa Nanomate (Advion Inc., Ithaca, 
NY) LC/MS sample manipulation robot. The robot took 1 μL extraction buffer and 
delivered the solution to the designated core to form a 1.5 μm liquid microjunction. The 
digested products were resolved in the liquid microjunction and extracted from tissue 
surface. This extraction process was repeated 5 times to enable maximum sample 
recovery from tissue surfaces. The optimum extraction buffer for digested GAGs and 
peptides was 0.3% ammonium and 10%ACN/90%water/0.1%FA solution, respectively.   
4.2.4 Development of a nano-fluidic HILIC-LC-MS/MS method to analyze digested 
heparan sulfate from TMAs 
 HILIC resins were de-packed from three 2.1mm*15cm chromatography columns 
(Thermo Dionex Glycan Pac AXH-1, Thermo Dionex Accucore Amide 150 and Waters 
BEH HILIC) and tested for heparan sulfate disaccharides separation. Nano-HILIC 
analytical capillary columns (100 μm* 15cm) were packed in-house. The columns were 
mounted on Waters NanoAcquity chromatograph coupled to a Q-Exactive plus mass 
spectrometer (ThermoFisher Scientific™, San Jose, CA). Tandem MS using HCD with 
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normalized collision energy of 30 eV was conducted to discriminate D2A0 from D0A6 
and D2S0 from D0S6. Mass spectra were acquired in the Orbitrap mass analyzer with 1 
microscan per spectrum for both MS and MS/MS in negative ionization mode. The 
resolving power for MS and MS/MS were set at 70,000 and 17,500. The precursor ion 
isolation window was set to 2 u. 
 The mobile phase A is 50mM ammonium formate, pH 4.4 and the mobile phase B 
is 95% ACN/5% HPLC water. The optimized LC gradient is shown in the table 4.1.  
Time (min) Flow rate (μl/min) %A %B 
0 0.6 7.5 92.5 
5 0.6 7.5 92.5 
30 0.6 50 50 
33 0.6 80 20 
35 0.6 80 20 
38 0.6 7.5 92.5 
55 0.6 7.5 92.5 
Table 4.1 Optimized LC gradient for nano-fluidic HILIC LC capillary column 
 
4.2.5 Development of a Micro-fluidic HILIC LC-MS/MS method to analyze digested 
chondroitin sulfate from TMAs 
 A 300 μm*15cm column (packed with 1.9 μm Thermo Dionex Glycan Pac AXH-
1 resin, a generous gift from Thermo Dionex), was mounted to Waters Acquity 
chromatograph. The was interfaced to a LTQ-Orbitrap XL mass spectrometer 
(ThermoFisher Scientific™, San Jose, CA). Tandem MS using CID with normalized 
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collision energy of 30 eV was conducted to discriminate D0a4 from D0a6. Mass spectra 
were acquired in the Orbitrap mass analyzer with 1 microscan per spectrum for both MS 
and MS/MS at negative mode. Resolving power for MS and MS/MS were set at 60,000 
and 15,000, respectively. The isolation window for targeted precursor is 3 u. 
 The mobile phase A is 50mM ammonium formate, pH 4.4 and the mobile phase B 
is 95% ACN/5% HPLC water. The LC is running at isobaric gradient at 85%B with 7 
μL/min. Each LC run was reduced to 20 min to maximize throughput.  
4.2.6 Nano-fluidic C18 LC-MS/MS for proteomics data acquisition  
 An analytical reverse phase C18 column (150μm*10cm, 1.7µm BEH C18 resin) 
and a trapping reverse phase C18 column (180μm*2cm, 5µm Symmetry™ C18 resin) 
were mounted into a Waters NanoAcquity, which is coupled with Thermo mass 
spectrometer QE plus (ThermoFisher Scientific™, San Jose, CA). Mass spectra were 
acquired in the Orbitrap mass analyzer with 1 microscan per spectrum for both MS and 
MS/MS at positive mode. Resolving power for MS and MS/MS were set at 70,000 and 
17,500 at m/z 400, respectively. The top 20 most abundant precursors is chosen for 
tandem MS with HCD fragmentation at normalized collision energy of 27v. The isolation 
window for precursor is 1.4 u. In addition, the dynamic exclusion of 10s was enabled for 
precursor selection.  
 The mobile phase A is 99% HPLC water /1% ACN/0.1%FA and the mobile phase 
B is 1% HPLC water/99% ACN/ 0.1% FA. The trapping event for the trapping column is 
4 μL/min with 100%A for 3 mins. The optimized LC gradient for the C18 analytical 
column is shown in the table 4.2. 
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Time (min) Flow rate (μl/min) %A %B 
0 0.5 98 2 
1 0.5 98 2 
91 0.5 60 40 
93 0.5 60 40 
96 0.5 2 98 
98 0.5 2 98 
102 0.5 98 2 
120 0.5 98 2 
Table 4.2 Optimized LC gradient for nano-fluidic C18 LC capillary column 
 
4.2.7 Progenesis for proteomics label free quantification  
 Commercial Progenesis LC-MS software was used for proteomics label free 
quantification.  We imported raw mass spectral data into Progenesis and performed 
retention time alignment among runs. This alignment is important to insure that a 
consistent set of feature is quantified across all LC-MS runs. Features were defined 
according to isotopic distributions present within a defined retention time window. 
Feature quantification was calculated using the area of monoisotopic peaks in the MS 
scan. The identities of the detected features were confirmed by search of the tandem mass 
spectra using a Mascot database search. The following parameters were used for Mascot 
database search: 2 miscleavages for the trypsin digestion; peptide precursor mass 
tolerance within 5ppm; MS/MS tolerance within 50 mmu; allowed variable modifications 
included deamidation (NQ), pyro-glutamate (N-terminal QE), carbamyl (N-terminal), 
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oxidation (M), hydroxylation (PK), and phosphorylation (ST). The identified peptide 
features were imported back into Progenesis. Proteins that contained at least 2 unique 
peptides are kept for the label free quantification.  
4.3 Results  
4.3.1 Nano-fluidic HILIC LC-MS/MS for analysis of HS disaccharides  
 In chapter 3, we demonstrated the reproducibility of SEC-MS to analyze heparan 
sulfate digested from histological slides (55). However, SEC-MS lacks the sensitivity 
necessary to analyze heparan sulfate quantities less than 30 fmol, the typical quantity 
released form from 1.5 mm TMA spots. In addition, one SEC-MS run requires 
approximately 3 hours. It would require at least 12 days to finish the data acquisition for 
two sets of molecular signatures (heparan sulfate and chondroitin sulfate) from 48 cores 
if we used SEC-MS. Therefore, SEC-MS was not suitable for large-scale data acquisition. 
Hydrophilic interaction liquid chromatography (HILIC) for GAGs was developed to 
reduce the LC run from 3 hours to 55 mins. 
 We firstly tested the Thermo Dionex Accucore Amide HILIC resin. Nano-fluidic 
columns (100 μm, 15cm) were packed with Accucore amide 150 resin (2.6 um particle 
size, partially porous particle with solid core) and tested for heparan sulfate disaccharides 
with 600 nL/min flow rate and 92.5%B as initial condition. High organic initial condition 
was applied to enable maximum binding capacity of heparan sulfate disaccharides to the 
column. As shown in the Figure 4.5, huge peaks of heparan sulfate disaccharides were 
eluted at 10 min, which are corresponding to the void volume of the LC setting. In the 
other words, the binding capacity for heparan sulfate disaccharides is not quite favorable 
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with Accucore amide 150 resin. Partially porous particle resin with solid core is known to 
have relatively lower backpressure than porous particle resin (203). However, the lower 
loading capacity with solid core particle (203,204) might contribute to the unsatisfactory 
binding of Accucore amide 150 for heparan sulfate disaccharides. Therefore, we decide 
to test fully porous HILIC resin from Waters.   
Figure 4.5 Accucore Amide 150 nano LC chromatography for HS disaccharides  
 
 1.7 μm fully porous HILIC resin was de-packed from a 2.1mm*15cm Waters 
BEH column and used for packing 100 μm*15cm nano-fluidic capillary columns. The 
heparan sulfate disaccharides were also tested with 600 nl/min flow rate and 92.5% B as 
initial condition. As shown in the Figure 4.6, huge peaks of heparan sulfate disaccharides 
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were again eluted at 9 mins. We observed higher abundances of heparan sulfate 
disaccharides bound to BEH HILIC resin than Accucore Amide 150 resin. However, the 
binding capacity for BEH HILIC is not optimal 
 
Figure 4.6 BEH HILIC nano LC chromatography for HS disaccharides  
 
 Mixed mode chromatography has been emerging as a powerful tool in separation 
of various compounds as at least two modes of interactions exist simultaneously to 
provide a wider range of separation (205-209). The Thermo Dionex GlycanPac AXH-1 
column combines both hydrophilic interaction liquid chromatography (HILIC) and weak 
anion exchange (WAX) retention mechanism for optimal resolving power and selectivity. 
The WAX provides functional retention and selectivity for negatively charged molecules 
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like sialylated N-glycans. Therefore, the HILIC-WAX resin was used to investigate the 
application for heavily sulfated sugars. As shown in the Figure 4.7, HILIC-WAX resin 
provides the best binding capacity and selectivity for heparan sulfate disaccharides. The 
more sulfate groups on the disaccharides, the harder it elute from the column. The same 
flow rate and initial condition is used for HILIC-WAX capillary column. We indeed 
observed the separation of resolution for the HILIC-WAX column decreased when it’s 
scaled down to nano-capillary column. Therefore, tandem MS/MS is enabled to 
discriminate isomer D2S0/D0S6 and D2A0/D0A6.  
 
Figure 4.7 HILIC-WAX nano LC chromatography for HS disaccharides  
 
4.3.2 Micro-fluidic HILIC LC-MS/MS for analysis of CS disaccharides  
 The abundance of chondroitin sulfate is much higher than that of heparan sulfate 
released from TMA. We are expected to detect at least 1 pmol total chondroitin sulfate 
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disaccharides from 1.5mm ID, 5μm thickness TMA cores. Therefore, we increased the 
flow rate in order to shorten the length of LC run. As shown in the Figure 4.8, isobaric 
gradient is used for the separation of CS disaccharides with a 300 μm*15 cm HILIC-
WAX column. Each LC run is completed in 20 mins with 7 μl/min flow rate, which 
significantly improve the analytical throughput for CS. 300 μm*15 cm HILIC-WAX 
column showed a certain extent resolving power for isomer D0a4/D0a6; however it’s not 
baseline separation. Therefore, CID tandem fragmentation is used to fully distinguish 
isomer D0a4/D0a6 based on the unique fragment ion for each structure.  
 
Figure 4.8 HILIC WAX micro LC chromatography for CS disaccharides 
 
4.3.3 Efficiency test for HSPIM and CS-SC with automated enzyme printing and 
tissue surface liquid extraction  
 Automated enzyme printing into tissue surface with CHIP-1000 and recovery of 
digested products from tissue surfaces with Nanomate liquid microjunction surface 
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extraction technique were developed in-house. Heparan sulfate from porcine intestinal 
mucosa (HSPIM) and chondroitin sulfate from shark cartilage (CS-SC) were spiked into 
the TMA tissue surfaces and used to monitor the quality of automated enzyme printing 
and liquid extraction process.  
 Triplicate of 0.01 ng, 0.05 ng, and 0.1ng HSPIM were spiked onto the TMA 
surfaces, followed by heparin lyases digestion. At the same time, triplicate of 0.01ng, 
0.05ng, and 0.1ng HSPIM were added into 500 μl eppendorf tube, followed by addition 
of heparin lyases in the tube. The digested HS disaccharides either from tissue surface 
digestion or eppendorf tube in-solution digestion were subjected into nano HILIC-LC-
MS/MS analysis. The efficiency of automated enzyme printing and liquid extraction is 
calculated based on the equation: Efficiency = (the abundance of HS disaccharide 
detected from tissue surface digestion/the average abundance of HS disaccharide detected 
from in-solution digestion)*100%. Similarly, triplicate of 10 ng, 25 ng, 50 ng, and 100 ng 
CS-SC were also tested for the efficiency of automated chondroitinase ABC enzyme 
printing and liquid surface extraction. Overall, the efficiency for each HS disaccharide 
from HSPIM and CS disaccharide from CS-SC is higher than 90%, as shown in the 
Figure 4.9 and Figure 4.10. In summary, the enzyme printing with CHIP-1000 and liquid 
surface extraction with Nanomate robot for HS and CS is consistently reproducible.   
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Figure 4.9 Enzyme printing and liquid surface extraction test for HSPIM 
 
 
Figure 4.10 Enzyme printing and liquid surface extraction test for CS-SC 
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4.3.4 Progenesis label free quantification test with HeLa whole cell lysate 
 In order to be confident about the performance of Progenesis, triplicate of 50 ng, 
100 ng, and 200 ng HeLa whole cell lysate tryptic peptides were subjected into C18 LC-
MS/MS data acquisition, followed by Progenesis label free quantification. More than 
2000 proteins with at least 2 unique peptides are used for quantification. The intensities 
for the total ion chromatography (TIC) are within the range of 50 ng, 100 ng, and 200 ng 
tryptic peptides from HeLa whole cell lysate digestion. Therefore, the performance test 
for Progenesis with HeLa whole cell lysate provided a general training guidance for the 
TMA proteomics data. As shown in the Figure 4.11 left panel, the median values for the 
coefficient of variances (CV) are all less than 10% for the triplicate of three different 
amount injection. We did observe outliers with CV higher than 20% or even reach 180%. 
We carefully checked the quantification of outlier proteins and found that over 80% of 
outliers are proteins with only 2 unique peptides and the abundance is low. Therefore, 
any proteins with only 2 unique peptides, which are enriched in the protein differential 
expression analysis, will be filtered out for the later statistical analysis and pathway 
analysis. When we normalized the lowest abundance of every specific protein among 
three different amount injections as 1 fold, we can observe that the triplicate 50 ng HeLa 
whole cell lysate are all within 1 fold range. And the 100 ng and 200 ng HeLa whole cell 
lysate triplicate injections are within 2 fold and 4 fold range, respectively (Figure 4.11, 
right panel). In summary, we believe that Progenesis provides excellent performance for 
label free quantification for complex proteomics data.  
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Figure 4.11 Progenesis label free quantification for tryptic peptides from HeLa 
whole cell lysate.  
Left: Coefficient of variance for triplicate injections of 50 ng, 100 ng, and 200 ng HeLa whole 
cell lysate. Right: The fold change for different amount injection of HeLa whole cell lysate.  
 
 We also spiked 50 ng, 100 ng, and 200 ng tryptic peptides of HeLa whole cell 
lysate onto tissue surfaces and tested the extraction recovery for complex peptide 
mixtures with Nanomate robot. As shown in the Figure 4.12, the recovery rates for 
triplicate 50 ng, 100 ng, and 200 ng are all higher than 90%, indicating the satisfactory 
extraction efficiency of Nanomate for peptide mixtures. Progenesis is also used for the 
quantification of Nanomate extracted HeLa whole cell lysate tryptic peptides. The 
recovery rate is calculated based on the following equation: Recovery rate = (the 
abundance of protein with Nanomate extraction/ the average abundance of protein in 
triplicate without Nanomate extraction)* 100% 
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Figure 4.12 Nanomate surface extraction recovery test for tryptic peptides of HeLa 
whole cell lysate.  
 
4.3.5 Proof of concept: reproducibility demonstration for quantitative glycomics and 
proteomics with three serial sections of TMA slides 
 In order to demonstrate the reproducibility of our analytical workflow, three serial 
sections of TMA slides were used, including 4 normal, 3 grade II, 4 grade III, and 4 grade 
IV astrocytoma cores. Astrocytoma is brain tumor that arises from the supportive 
astrocytes. Astrocytoma is graded on a scale from I to IV based on the tumor 
invasiveness and malignancy (210-216). Grade I and II are low grade astrocytomas, 
which are usually localized and grow slowly. However, grade III and grade IV are high 
grade astrocytomas, which grow rapidly and are extremely invasive. Glioblastoma (GBM) 
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is grade IV astrocytoma, which is deadly and malignant tumor with median survival time 
less than 15 months (217,218). In total, three datasets including heparan sulfate, 
chondroitin sulfate, and proteomics for 45 samples were acquired randomly.  
 Principal component analysis (PCA) is a widely used mathematical and statistical 
algorithm that is extremely helpful in displaying, extracting, and ranking variances within 
datasets. In datasets with multiple groups of variances, different variances often show 
similar behavior so that lead to redundant information. PCA is powerful in reducing the 
number of dependent variance in the datasets by replacing groups of intercorrelated 
variances with a new variance. The new generated sets of new variances are so-called 
principle components (PCs). Recently, PCA is widely used to process the mass 
spectrometry datasets which contain extremely complex and multiple dimensional 
information (219,220). Principal component analysis (PCA) is used to test the 
reproducibility of quantitative glycomics and proteomics as well as the correlationship 
between different grades of astrocytomas. 
 As shown in Figure 4.13, both the relative and absolute abundance for HS 
disaccharides from three serial sections for 15 samples cluster tightly with each other, 
demonstrating the good reproducibility of our method. The coefficient of variance for 
relative and absolute abundance of HS disaccharides is less than 15%. Similarly, PCA 
plot demonstrated excellent reproducibility for the relative abundance and absolute 
abundance for CS disaccharides and label free quantification proteomics data (Figure 
4.14 and 4.15). As shown in Figure 4.15, the abundance of EGFR and CD44 are 
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relatively higher in grade III/IV tumor than in grade II/normal, which is consistent with 
previous publications (221-228).  
 
Figure 4.13 PCA plot for HS disaccharides relative abundances (right) and absolute 
abundances (left) 
 
 
Figure 4.14 PCA plot for CS disaccharides relative abundances (right) and absolute 
abundances (left) 
 
The relative abundances for HS dp2s  The absolute abundances for HS dp2s  
The relative abundances for CS dp2s  The absolute abundances for CS dp2s  
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Figure 4.15 PCA plot for proteomics label free quantification (top) and the 
expression profile of EGFR and CD44 among dataset  
 
 
Figure 4.16 Combined PC1 and PC2 for grouping different grades of astrocytomas  
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 Interestingly enough, we observed that PCA is also useful in grouping different 
grades of astrocytomas. As shown in Figure 4.15 and 4.16, combined PC1 and PC2 of 
label free quantification proteomic and the relative abundance of CS datasets can group 
normal samples and grade II astrocytoma samples with A1 as an outlier. In addition, the 
relative abundance of HS disaccharides demonstrated the significantly different pattern 
between high grade III/IV tumor and low grade II/normal samples. More samples for 
each grade will be included in the future in order to increase the statistical power.   
4.4 Discussions and conclusions 
4.4.1 High-throughput method to integrate glycomics and proteomics 
 With multiple enzymatic digestion workflow on TMA tissue surfaces, sensitive 
nano HILIC-LC-MS/MS method and proteomics label free quantification, we 
successfully integrate glycomics and proteomics in a timely and costly efficient manner. 
In addition, we significantly reduce the intra-tumor heterogeneity and increase the spatial 
resolution for mass spectrometry profiling of glycans and proteins as the tissue volumes 
for TMA cores are less than 10 nl. Our method is high-throughput, efficient, and 
reproducible for both quantitative glycomics and proteomics, which allows for 
acquisition of integrated omics on a cohort large enough to read statistically significant 
conclusion.  
4.4.2 Future application to understand key steps during tumor pathogenesis  
 With our experimental workflow, we can investigate the alterations in molecular 
signatures for a detailed tumor heterogeneity study. TMA can be built from cores 
punched from the solid tumor center as well as tumor/normal tissue margins, which 
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would help researchers understand the critical tumor pathogenesis steps such as tumor 
metastasis and migration, proliferation, angiogenesis, and immune response. 
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Chapter 5. Glycomics, Glycoproteomics, and Proteomics for Different Subtypes of 
Glioblastoma Biospecimens 
5.1 Introduction  
5.1.1 Glioblastoma subtypes 
 Glioblastoma (GBM) is the most common and malignant primary brain tumor in 
human adults (229). It is a deadly human cancer with median survival time less than 15 
months with traditional treatment including surgical resection, radiotherapy, and 
chemotherapy (230). GBM is characterized by the aberrant activation of multiple RTK 
signaling pathways and poor prognosis. Therapies targeting RTK signaling pathways 
have achieved only limited clinical success (231). Genomics expression studies for GBM 
revealed four distinct transcriptional subclasses (classical, proneural, mesenchymal, and 
neural) characterized by abnormalities in EGFR, PDGFRA, IDH1, and NF1 (226). The 
classical subtype is defined by EGFR amplification, PTEN loss, and CDKN2A loss. The 
proneural subtype is characterized by the alterations of PDGFRA and mutations in IDH1. 
The mesenchymal subtype displays a high frequency of NF1 mutation. The neural 
subtype is not clearly defined by unique genomic signatures. In conclusion, GBM is 
highly heterogeneous tumor type.  
5.1.2 Proteoglycan and glioblastoma 
 Heparan sulfate proteoglycans (HSPGs) and chondroitin sulfate proteoglycans 
(CSPGs) are reported to be involved in the regulation of many RTK signaling pathways 
and to participate in cell-extracellular matrix (ECM) interaction (232-238) related to 
brain cancers.  HSPG and the extracellular HS modifying enzyme Sulf2 have been 
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implicated in the tumorigenesis of GBM (38). As shown in the Figure 5.1, the increased 
expression of Sulf2 activated PDGFRα signaling pathway in GBM by release of 
sequestered PDGF from ECM heparan sulfate proteoglycans.   
 
Figure 5.1 Heparan sulfate proteoglycan and Sulf2 regulate PDGFRα signaling 
pathway in GBM, adapted from reference (38,232) 
 
 A comprehensive genomic analysis was conducted with data from The Cancer 
Genome Atlas (TCGA) (239) in order to better understand the alterations of 
proteoglycans and their modifying enzymes for GBM. As shown in the Figure 5.2, 
multiple proteoglycan core proteins and glycosaminoglycan-modifying enzymes were 
differentially expressed in GBM relative to normal brain tissues. For example, the mRNA 
GBM Normal 
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by Sulf2 
Normal GBM 
Growth factors are bound 
to HSPG through 6-O-SO3 
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expression level for the majority of glypicans, syndecans, and ECM CSPGs like brevican, 
neurocan, and versican were significantly increased in GBM. Interestingly enough, GBM 
subtype-specific expression patterns for proteoglycan and glycosaminoglycan-modifying 
enzymes were also observed from TCGA data. Sulf1 and Sulf2 expression levels are low 
in neural and classical subtype while high in proneural and mesenchymal subtypes. 
 
Figure 5.2 The alteration of proteoglycans and glycosaminoglycan-modifying 
enzymes in GBM 
 
 In order to acquire a comprehensive understanding about the biological functions 
of proteoglycan in GBM tumorigenesis, and to identify biomarker candidates, we studied 
the alterations of glycosaminoglycan (HS and CS), the core proteins of proteoglycans, 
and other PG functional related proteins for different GBM subtypes.  
Proteoglycan Core proteins       GAG modifying enzymes 
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5.2 Experimental section  
5.2.1 Materials 
 Formalin fixed paraffin embedded (FFPE) tissue microarrays were constructed by 
Dr. Joanna Philips at University of California, San Francisco. Chondroitinase ABC 
enzyme was from Sigma-Aldrich. Heparan sulfate disaccharides and chondroitin sulfate 
disaccharides were purchased from Celsus Laboratories (Cincinnati, OH). Heparin lyases 
I, II, and III were generous gifts from Prof. Jian Liu (UNC Eshelman School of 
Pharmacy, USA). 2.1mm*15cm and 300μm*15cm GlycanPac AXH-1 column were 
generous gifts from Thermo Fisher Scientific
TM
 (San Jose, CA). Trypsin gold, mass 
spectrometry grade was from Promega Corp (Madison, WI). More detailed information 
regarding with the experimental materials are shown in the chapter 4.  
5.2.2 Protein differential expression analysis for proteomics data  
 Label free quantification data are exported from Progenesis and further 
normalized with the size of TMA cores. After label-free quantification and abundance 
normalization, protein differential expression and fold change were calculated. 
Differential expression was computed for each protein under a one-vs-all two sample t-
test design: 
     
          
 
    
 
  
 
     
 
   
 
where      is the mean of protein abundance   in condition  ,       is the mean of protein 
abundance   in conditions other than  ,     
  is the variance of protein abundance in 
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condition  ,      
  is the variance of protein abundance in conditions other than  ,    is 
the number of samples in condition  , and     is the number of samples in conditions 
other than  . The student’s t statistic from each test was converted into a p-value, and the 
set of p-values were adjusted using the Benjamini and Hochberg procedure to control the 
false discovery rate. 
 Fold change for each protein was also computed using a one-vs-all design: 
   
    
 
5.2.3 Ingenuity pathway analysis (IPA) for protein differential expression analysis  
 The fold change data generated from protein differential expression analysis was 
imported into ingenuity pathway analysis (IPA). The negative inverse (-1/x) was taken 
for fold change values between 0 and 1. Values greater than 1 were not affected. For 
example, 0.5 was inversed into -2, which represented 2-fold downregulation. The IPA 
core analysis was conducted for the imported fold change data for different GBM 
subtypes. The cutoff for the imported data was set as 3 for pathway analysis. Generally, 
the IPA core analysis corresponded to the process of mapping data to the IPA knowledge 
base, creating molecular algorithmically generated networks, dividing data into diseases 
and biological functions, and determining over represented either upregulated or 
downregulated signaling and metabolic canonical pathways. The top regulator effect 
networks and top canonical pathway networks were exported from IPA.  
5.2.4 Identification of posttranslational modification for proteomics data with 
PEAKS software  
 The commercial software PEAKS was used for the de novo sequencing of protein 
post-translational modifications (PTMs). The raw data files were imported into PEAKS. 
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The combined searches for de novo, database, and error tolerant PTMs were conducted 
against Uniprot. A 10 ppm error tolerance for the MS and 0.05 Da mass error tolerance 
for MS
2
 were specified for PEAKS searches. A maximum of two miscleavages for 
trypsin digestion was allowed. The false discovery rate (FDR) of 0.1% was used to allow 
PSMs (peptide-spectrum-matches) with -10logP values higher than 15. The PTMs data 
were exported from PEAKS to calculate the frequency of biological function related 
PTMs.  
5.2.5 Glycopeptides identification and quantification  
 The EIC for m/z = 203.0794 (the oxonium ion of HexNAc) was extracted to 
indicate glycopeptides tandem spectra. The m/z for the precursor monoisotopic peak and 
the charge state for the glycopeptides precursors were determined manually based on the 
isotopic distribution pattern. The m/z for the aglycon monoisotopic peak and the charge 
state for the aglycon were determined by tracing the sequential neutral loss of 
monosaccharide. The molecular weight for the attached glycan is calculated by the mass 
difference between precursor glycopeptides and aglycon. The GlycoMod (240) tool was 
used to calculate the possible composition of glycans within 5 ppm mass range. A 
database containing tryptic peptides generated from Progenesis label free quantification 
with two miscleavages was used to match the aglycon of glycopeptides within 10 ppm. In 
addition, the fragment b and y ions of candidate tryptic peptides were also used to match 
the tandem mass spectrum of glycopeptides. The sequence for the aglycon was confirmed 
if the sequence coverage with matched b and y ions for the candidate tryptic peptides was 
over 40% for N-glycopeptides and 60% for O-glycopeptides. The glycosylation site for 
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both N-glycosylation (NXT/S) and O-glycosylation (S/T) was carefully assigned with 
manual interpretation for the tandem mass spectrum. The area for the monoisotopic peak 
of the identified glycopeptide was used for the quantification of glycopeptide.   
 The detailed tissue surface digestion workflow for TMAs and quantification 
method for HS/CS disaccharides and proteins are shown in the chapter 4 Figure 4.3.  
5.3 Results  
 In this study, 43 the TMA biospecimens were subjected into HS/CS/protein 
analysis with the experimental workflow shown in the Figure 4.4, including 4 cores for 
normal tissues, 2 cores for GBM neural subtype, 6 cores for GBM mesenchymal subtype, 
10 cores for GBM proneural subtypes, 6 cores for GBM classical subtype, and 15 cores 
with unknown GBM subtype information. Three datasets for HS disaccharides, CS 
disaccharides, and proteomics were acquired randomly and blindly. The TMA 
biospecimens were coded and analyzed randomly, with the key held by our collaborator 
Dr. Joanna Phillips at UCSF until the completion of data acquisition and analysis.  
5.3.1 Decreased HS 6-O-SO3 in GBM classical subtype 
 Hierarchical clusters were generated for the relative abundances of HS 
disaccharides in order to compare the HS expression pattern in different GBM subtypes. 
As shown in the Figure 5.3 left panel, cores labeled with classical subtype are grouped 
together and distinguishable from other subtypes. Except for neural subtype, the relative 
abundance for (D2S6+D0S6) in GBM is lower than normal tissues. To be more specific, 
the relative abundance for (D2S6+D0S6) is lowest in classical subtype as shown in the 
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Figure 5.3 right panel. The reduced HS 6-O-SO3 might due to the upregulated sulfatase or 
downregulated sulfotransferase enzymatic activity. 
 
 
Figure 5.3 The relative abundances of HS dp2s for different subtypes of GBM 
 
 The relatively lower expression of Sulf1 and Sulf2 in neural and classical subtype 
(38,239,241) is consistent with the higher HS 6-O-SO3 degree in our result. However, we 
should also expect to observe relatively higher HS 6-O-SO3 level in classical subtype, 
which is contradictory with our results. Therefore, we suspect that the abundances of 
enzyme activities of certain HS sulfotransferases should be much lower in classical 
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subtype in order to compromise the lower sulfatase expression and make HS 6-O-SO3 
degree significantly lower than all the other GBM subtypes.  
5.3.2 Increased CS 6-O-SO3 in GBM mesenchymal subtype 
 Except for neural subtype, the relative abundance of CS D0a6 in GBM is higher 
than normal tissues. Among the 4 GBM subtypes, mesenchymal contains the highest 
percentage of CS D0a6, as shown in the Figure 5.4. Unlike the reduced expression of HS 
6-O-SO3 that may contribute to the activation of RTK signaling pathways (38), the 
potential biological functions for the elevated CS 6-O-SO3 are unknown. 
 
Figure 5.4 The relative abundance of CS D0a6% for different subtypes of GBM 
 
5.3.3 Protein differential expression analysis for different GBM subtypes 
 Approximately 2000 proteins with at least 2 unique peptides are quantified with 
Progenesis for this dataset. The quantified data were exported from Progenesis and 
subjected to R statistical one-vs-all calculation for the differential expressed proteins in 
different GBM subtypes and normal tissues. A heat map with hierarchical clustering was 
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generated (Figure 5.5) for all the differential expressed proteins. It is clear that the 
majority of classical and proneural subtypes clustered together with higher global protein 
expression. On the other hand, the normal tissue, neural subtypes, and mesenchymal 
subtypes clustered together with lower global protein expression. In summary, different 
expression pattern of proteins for subtypes were detected. 
 
Figure 5.5 Hierarchical clustering for differential expression proteins among 
different types of GBM 
 
 Protein fold change for different subtypes is also computed with one one-vs-all 
design. We listed the upregulated proteins in each subtype in the Table 5.1. 
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MES CLA PRO NEU 
GNS_HUMAN, 14.7 
POSTN_HUMAN, 14.1  
RAB3I_HUMAN, 10.5 
HV304_HUMAN, 9.3 
COBA1_HUMAN, 7.5 
CO1A2_HUMAN, 7.4 
COCA1_HUMAN, 7.4 
LUM_HUMAN, 7.3 
MIME_HUMAN, 7.0 
RAB21_HUMAN, 6.5 
FIBG_HUMAN, 6.4 
FIBB_HUMAN, 6.3 
FIBA_HUMAN, 6.3 
CO1A1_HUMAN, 6.0 
GLNA_HUMAN, 6.0 
CO3A1_HUMAN, 5.5 
IGHM_HUMAN, 5.1 
APOB_HUMAN, 5.0 
KV101_HUMAN, 4.6 
CAND1_HUMAN, 4.0 
FKB10_HUMAN, 4.0 
BSN_HUMAN, 4.0 
KV301_HUMAN, 4.0 
IGKC_HUMAN, 3.7 
EMC1_HUMAN, 3.6 
DNJC8_HUMAN, 3.6 
ARP3_HUMAN, 3.5 
PGS1_HUMAN, 3.5 
CO5A2_HUMAN, 3.3 
COR2B_HUMAN, 3.2 
RAP1B_HUMAN, 3.2 
IP3KB_HUMAN, 3.2 
CO6A1_HUMAN, 3.2 
AACT_HUMAN, 3.0 
HEMO_HUMAN, 3.0 
CO6A2_HUMAN, 3.0 
HV301_HUMAN, 3.0 
TAGL_HUMAN 
 
LIMC1_HUMAN, 7.0 
CA198_HUMAN, 6.1 
PCCB_HUMAN, 5.9 
DHE3_HUMAN, 5.7 
DCXR_HUMAN, 5.2 
MMSA_HUMAN, 4.0 
CD166_HUMAN, 3.9 
CRYL1_HUMAN, 3.5 
CSPG2_HUMAN, 3.2 
CAYP1_HUMAN, 3.2 
CACP_HUMAN, 3.1 
PGCB_HUMAN, 3.0 
S6A11_HUMAN, 3.0 
 
ANK1_HUMAN, 13.2 
CAH1_HUMAN, 7.6 
PDCD5_HUMAN, 6.0 
CD2A1_HUMAN, 5.7 
NNMT_HUMAN, 5.5 
HBB_HUMAN, 5.5 
SODM_HUMAN, 5.5 
PIR_HUMAN, 5.2 
NQO1_HUMAN, 5.0 
TRFL_HUMAN, 4.7 
TYPH_HUMAN, 4.7 
HBA_HUMAN, 4.6 
CO5A3_HUMAN, 4.5 
S10A9_HUMAN, 4.4 
B3AT_HUMAN, 4.3 
CXA1_HUMAN, 4.1 
CAH3_HUMAN, 4.1 
CBR1_HUMAN, 4.0 
LMNA_HUMAN, 3.9 
PLCD1_HUMAN, 3.8 
FABP5_HUMAN, 3.8 
KAP3_HUMAN, 3.6 
RET1_HUMAN, 3.5 
NAMPT_HUMAN, 3.5 
GST2_HUMAN, 3.4 
SYWC_HUMAN, 3.3 
SPRE_HUMAN, 3.3 
DSRAD_HUMAN, 3.2 
EGFR_HUMAN, 3.2 
VAT1L_HUMAN, 3.2 
HSPB6_HUMAN, 3.1 
KAT3_HUMAN, 3.1 
PEPL_HUMAN, 3.1 
HPT_HUMAN, 3.1 
CD99_HUMAN, 3.0 
 
SAMP_HUMAN, 102.2 
ABCF3_HUMAN, 21.1 
RBM39_HUMAN, 4.6 
RCC2_HUMAN, 3.8 
 
Table 5.1 Upregulated proteins in different subtypes of GBM 
 
 Protein fold change data were subjected to IPA core pathway analysis. As shown 
in the Figure 5.6, the top network enriched for classical subtype was cellular function and 
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maintenance, molecular transport, small molecular biochemistry. Significantly elevated 
chondroitin sulfate proteoglycans (CSPGs), brevican and versican, were shown with 
malfunctions in cell-cell adhesion and cancer invasion.  
 
Figure 5.6 Top network enriched in IPA for GBM classical subtype 
 
 For the mesenchymal subtype, we observed significantly higher expression of 
ECM molecules including collagens, fibrinogen, lumican and biglycan, which are 
enriched in the cancer, connective tissue disorders, organismal injury and abnormalities 
network (Figure 5.7). Lumican and biglycan, two members of the CSPG family, were 
detected only in the mesenchymal subtype. Therefore, the alteration in these proteins 
might serve as biomarkers for mesenchymal subtype. 
Cellular function and maintenance, molecular transport, small molecular biochemistry  
Versican  
Brevican 
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Figure 5.7 Top network enriched in IPA for GBM mesenchymal subtype 
 
 For the proneural subtype, the activation of IL-1 as an upstream effector molecule 
was pinpointed as the expressions of EGFR, GJA1, SOD2, S100A9, and TYMP were 
upregulated, as shown in the Figure 5.8.  
 As demonstrated in the Figure 5.9, the significantly downregulated expression of 
downstream molecules for growth factor signaling pathway such as STAT3, NRCAM, 
SYNM, and ALCAM suggests the lowest ability in tumor invasiveness and angiogenesis 
for neural subtype compared with the other subtypes. Not surprisingly, normal tissues 
were shown to have inactivated tumor cell movement, connective tissue migration, and 
infiltration of neutrophils in the Figure 5.10. Therefore, we concluded that the neural 
subtype phenotype most closely resembles that of normal tissues.  
Cancer, connective tissue disorders, organismal injury and abnormalities   
biglycan 
collagens 
fibrinogen 
lumican 
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Figure 5.8 Predicated activation of IL1 as top regulator effector network for GBM 
proneural subtype 
 
 
Figure 5.9 Predicated inactivation of tumor invasiveness and angiogenesis for GBM 
neural subtype 
 
Predicted activation of IL1 as top regulator effect network  
EGFR 
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invasiveness 
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Figure 5.10 Predicted inactivation of tumor cells and connective tissue cells 
migration and infiltration of neutrophils for normal tissue 
 
5.3.3 Glycoproteomics in GBM 
 PEAKS software was used to analyze the protein posttranslational modifications 
(PTMs). As demonstrated in Figure 5.11, we observed FFPE induced modifications 
(formylation and methyl ester), sample preparation induced modifications (oxidation, 
deamidation, and pyro-glutamate formation), and biological function-related 
modifications, among which the hydroxylation on P/K for collagens and protein 
acetylation were the most abundant forms. About four hundred tandem mass spectra were 
extracted from our proteomics data that contained the EIC HexNAc oxonium ion, a 
signature fragment ion for protein glycosylation.  To our surprise, peptides with such 
glycosylation corresponded in abundance to 24% of the biological function related 
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connective tissue cells  
Infiltration of 
neutrophils 
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modifications. Therefore, we looked more closely for protein glycosylation in our 
proteomics dataset. 
 
Figure 5.11 Protein glycosylation as one of the important biological function related 
PTMs 
 
 
Figure 5.12 Spectrin O-HexNAc glycosylation 
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Figure 5.13 Neurocan N-glycosylation  
 
 
Figure 5.14 Versican O-glycosylation  
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 Figure 5.12, 5.13, and 5.14 show representative tandem mass spectra for protein 
O-HexNAc, N-glycosylation and O-glycosylation identified with a manual de novo 
sequencing strategy. In order to increase the throughput for interpretation of protein 
glycosylation data, we developed a semi-automated workflow to assist the data analysis. 
Briefly, the EIC for the oxonium ion of HexNAc were extracted and picked from tandem 
spectra with a scan tool built in-house. In order to accurately determine the molecular 
weight of glycopeptide precursors and aglycons, we manually assigned the monoisotopic 
peak and charge state for the precursor and fragment ions. The possible compositions for 
glycans were calculated using GlycoMod based on the mass difference of glycopeptide 
and aglycon.  In order to determine the peptide sequence of aglycon, a database 
containing tryptic peptides was generated from Progenesis label free quantification 
proteome output. A maximum of two miscleavages was allowed to match the aglycon 
sequence within 10 ppm. A list of peptide candidates were generated from MS matching. 
In order to confirm the detailed peptide sequence, the theoretical fragment b and y ions of 
candidate peptides were also used to match the experimental tandem mass spectrum of 
glycopeptides. The sequences for the aglycon were confirmed if the sequence coverage 
with matched b and y ions for the candidate tryptic peptides was over 40% for N-
glycopeptides and 60% for O-glycopeptides, respectively. The glycosylation site for both 
N-glycosylation (NXT/S) and O-glycosylation (S/T) was carefully assigned with manual 
interpretation for the MS/MS spectra. With this strategy, about 90% of the tandem mass 
spectra containing HexNAc oxonium ion were assigned. In total, 62 and 38 glycoforms 
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for O-glycosylation and N-glycosylation were detected from our proteomics HCD 
dataset, as shown in Tables 5.2 and 5.3 
 
 
Table 5.2 List of protein O-HexNAc and O-glycosylation  
 
Type of glycosylation Protein (# of glycopeptide) Peptide (# of glycoform) Glycan composition
Spectrin beta chain, non-erythrocytic 1 (1) HEVSASTQSTPASSR (1) O -GlcNAc
Catenin delta-2 peptide (1) SYSTSSPINIVVSSAGLSPIR (1) O -GlcNAc
Neurocan core protein (1) ETGETSPAQVNK (1) (Hex)1(HexNAc)1(NeuAc)1
Ankyrin-2 (1) GANIHMSTK (1) (Hex)1(HexNAc)1(NeuAc)2
(Hex)1(HexNAc)1(NeuAc)1
(Hex)1(HexNAc)1(NeuAc)2
(Hex)2(HexNAc)2
(Hex)3(HexNAc)3
(Hex)2(HexNAc)2(NeuAc)1
(Hex)2(HexNAc)2(NeuAc)2
(Hex)2(HexNAc)2(NeuAc)3
(Hex)3(HexNAc)3(NeuAc)1
(Hex)3(HexNAc)3(NeuAc)2
(Hex)3(HexNAc)3
(Hex)3(HexNAc)3(NeuAc)1
(Hex)3(HexNAc)3(NeuAc)2
(Hex)1(HexNAc)1
(Hex)1(HexNAc)1(NeuAc)1
(Hex)1(HexNAc)1(NeuAc)2
(Hex)1(HexNAc)1(NeuAc)2
(Hex)2(HexNAc)2(NeuAc)2
(Hex)2(HexNAc)2(NeuAc)3
(Hex)2(HexNAc)2(NeuAc)4
Mucin type O -glycosylation
O -GlcNAc
Brevican core protein (5) 
(E)SLSQAPAR (2)
VHGPPTETLPTPR (7)
NLASPSPSTLVEAR (3)
EVGEATGGPELSGVPR (4)
AVLQPGASPLPDGESEASRPPR (3)
Type of glycosylation Protein (# of glycopeptide) Peptide (# of glycoform) Glycan composition
 FTIR (1) (Hex)1(HexNAc)1(NeuAc)2
 ITEEFLGK (1) (Hex)1(HexNAc)1
(Hex)2(HexNAc)2(NeuAc)1
(Hex)2(HexNAc)2(NeuAc)2
LSAEPTEVR (1) (Hex)1(HexNAc)1(NeuAc)2
(Hex)2(HexNAc)2
(Hex)2(HexNAc)2(NeuAc)1
(Hex)2(HexNAc)2(NeuAc)2
(Hex)2(HexNAc)2
(Hex)2(HexNAc)2(NeuAc)1
(Hex)2(HexNAc)2
(Hex)2(HexNAc)2(NeuAc)1
(Hex)2(HexNAc)2(NeuAc)2
TEEEVFSGMK (1) (Hex)1(HexNAc)1
TEEEVFSGM(oxidation)K (1) (Hex)1(HexNAc)1
SFDFPTLITK (1) (Hex)1(HexNAc)1(NeuAc)2
(Hex)1(HexNAc)1(NeuAc)1
(Hex)1(HexNAc)1(NeuAc)2
 (Hex)3(HexNAc)4
 (Hex)4(HexNAc)4
 (Hex)4(HexNAc)4
 (Hex)4(HexNAc)4
 (Hex)4(HexNAc)4(NeuAc)1
 (Hex)4(HexNAc)4(NeuAc)2
YLSTTPFPSQHR (1) (Hex)3(HexNAc)3
EFPVTETPLVTAR (1) (Hex)3(HexNAc)3
QTSGRITEEFLGK (1) (Hex)2(HexNAc)2(NeuAc)2
QLEEVTDEDIAAH (1) (Hex)1(HexNAc)1
(Hex)4(HexNAc)4
 (Hex)5(HexNAc)5
(Hex)5(HexNAc)6
(Hex)5(HexNAc)7
(Hex)4(HexNAc)6(NeuAc)1
(Hex)4(HexNAc)6(NeuAc)1
(Hex)4(HexNAc)6(NeuAc)1
(Hex)5(HexNAc)5(NeuAc)1
(Hex)5(HexNAc)6(NeuAc)1
(Hex)6(HexNAc)6(NeuAc)1
QLEEVTDEDIAAHGK with N-terminal pyroglutamate (1) (Hex)1(HexNAc)1
(Hex)1(HexNAc)1
(Hex)1(HexNAc)1(NeuAc)1
Mucin type O-glycosylation Versican core protein (19)
ETETDIDR (2)
VSLSPGPEQK (3)
TDEVVTLTPR (2)
VPVLETTPVGK (3)
LEATISPETMR (2)
FQPTTSTGIAEK (6)
LHTTSAFKPSSAITK (10)
QLEEVTDEDIAAHGK (3)
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Table 5.3 List of protein N-glycosylation 
 
 To our surprise, the two major core proteins for protein O-glycosylation were 
versican and brevican, two members of the hyalectican CSPGs. Interestingly, we 
observed that the classical subtype tends to have more glycosylation than the other 
subtypes and normal tissues, as shown in the Figure 5.15 (right panel). We also 
calculated the sialylation degree for the O-glycosylation based on the following equation: 
sialylation degree = (the abundance of glycopeptides with sialic acid/ the total abundance 
Type of glycosylation Protein (# of glycopeptide) Peptide (# of glycoform) Glycan composition
BDNF/NT-3 growth factors receptor (1)  NLTIVDSGLK (1) (Hex)3+(Man)3(GlcNAc)2
Cathepsin D protein peptide (1) GSLSYLNVTR (1) (Hex)3+(Man)3(GlcNAc)2
Complete C3 (1) TVLTPATNHMGNVTFTIPANR (1) (Hex)3+(Man)3(GlcNAc)2
Neurocan core protein (1) ANATLLLGPLR (1) (Hex)2+(Man)3(GlcNAc)2
Receptor-type tyrosine-protein phosphatase zeta (1) TVEINLTNDYR (1) (Hex)2+(Man)3(GlcNAc)2
Brevican core protein peptide (1) TLFLFPNQTGFPNK (1) (Hex)1(HexNAc)3(Fuc)2+(Man)3(GlcNAc)2
Alpha-1-antitrypsin (1) YLGNATAIFFLPDEGK (1) (Hex)2(HexNAc)2(NeuAc)2+(Man)3(GlcNAc)2
Alpha-1-acid glycoprotein 2 (1) NEEYNK(S) (1) (Hex)2(HexNAc)2(NeuAc)2+(Man)3(GlcNAc)2
(Hex)2(HexNAc)2(Fuc)1+(Man)3(GlcNAc)2
(HexNAc)3(Fuc)1+(Man)3(GlcNAc)2
(Hex)3+(Man)3(GlcNAc)2
(Hex)2+(Man)3(GlcNAc)2
GTEWLVNSSR (1) (Hex)2+(Man)3(GlcNAc)2
(HexNAc)3(Fuc)1+(Man)3(GlcNAc)2
(Hex)1(HexNAc)3(Fuc)2+(Man)3(GlcNAc)2
 FHVNYTQPLVAVK (1) (Hex)3+(Man)3(GlcNAc)2
(Hex)2+(Man)3(GlcNAc)2
(Hex)3+(Man)3(GlcNAc)2
LNYS(L) (1) (Hex)2+(Man)3(GlcNAc)2
NTTSYVLR (1) (Hex)2+(Man)3(GlcNAc)2
NTTSY(V) (1) (HexNAc)3(Fuc)1+(Man)3(GlcNAc)2
(Hex)2+(Man)3(GlcNAc)2
(HexNAc)3(Fuc)1+(Man)3(GlcNAc)2
(Hex)1(HexNAc)3(Fuc)2+(Man)3(GlcNAc)2
LNYSLPTGQWVGVQLPR (1) (Hex)2+(Man)3(GlcNAc)2
(Hex)1(HexNAc)2+(Man)3(GlcNAc)2: G1
(Hex)1(HexNAc)3+(Man)3(GlcNAc)2: G1B
(Hex)2(HexNAc)2+(Man)3(GlcNAc)2: G2
(HexNAc)2(Fuc)1+(Man)3(GlcNAc)2: G0F
(Hex)1(HexNAc)2(Fuc)1+(Man)3(GlcNAc)2: G1F
(Hex)2(HexNAc)2(Fuc)1+(Man)3(GlcNAc)2: G2F
(HexNAc)3(Fuc)1+(Man)3(GlcNAc)2: G0FB
(Hex)2(HexNAc)3(Fuc)1+(Man)3(GlcNAc)2: G2FB
(Hex)2(HexNAc)2(Fuc)1(NeuAc)1+(Man)3(GlcNAc)2: G2FS
(HexNAc)2(Fuc)1+(Man)3(GlcNAc)2: G0F
(Hex)1(HexNAc)2(Fuc)1+(Man)3(GlcNAc)2: G1F
(Hex)2(HexNAc)2(Fuc)1+(Man)3(GlcNAc)2: G2F
(Hex)2(HexNAc)2(Fuc)1(NeuAc)1+(Man)3(GlcNAc)2: G2FS
N -glycosylation
Versican core protein (1)  FENQTGFPPPDSR (2)
Neuronal cell adhesion molecule (1) NGTHFDIDK (2)
Ig gamma-1 chain C region (1) EEQYNSTYR (9)
Ig gamma-2 chain C region (1) EEQFNSTFR (4)
Contactin-1 (Glycoprotein gp135) (2)
ANSTGTLVITDPTR (2)
Sodium/potassium-transporting ATPase subunit beta-2 (2)
FLEPYNDSIQAQK (2)
Tenascin (5)
NLTVPGSLR (3)
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of glycopeptides for the protein)*100%. In general, GBM tumors had more O-
glycopeptides with sialic acid modification for versican and brevican than normal tissue, 
as shown in the Figure 5.17 (left panel). Among the 4 different subtypes, classical was 
distinguishable because it contained highest sialylation degree for versican and brevican. 
The sialylation degree in neural subtype was close to normal tissues. 
 
Figure 5.15 Increased brevican and versican O-glycosylation with higher degree of 
sialylation for GBM classical subtype 
 
5.4 Discussions and conclusions 
5.4.1 GBM subtype specific pattern of glycomics, glycoproteomics, and proteomics 
 Based on our results for glycomics (HS and CS), glycoproteomics, and 
proteomics, we observed distinct patterns for each GBM subtype. One of the most 
interesting discoveries is the similarity between neural subtype and normal tissues in the 
HS 6-O-SO3 and CS 6-O-SO3 levels, sialylation degree of brevican and versican O-
glycosylation, and the whole proteome. Our conclusion is consistent with previous 
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TCGA publications claiming that the neural subtype might be “contaminating” normal 
tissue (226,242). The classical subtype showed significantly decreased HS 6-O-SO3 and 
elevated brevican and versican sialylation degrees. Brevican and versican are the major 
components of brain extracellular matrix (ECM), which are organized into three principal 
compartments including the basement membrane, the perineuronal nets and the neural 
interstitial matrix. Both perineuronal nets and the neural interstitial matrix comprise 
dense networks of hyaluronan, tenascins, link proteins, and proteoglycans including 
versican and brevican (243). Therefore, the potential functions of the increased 
sialylation in versican and brevican bear further investigation. The mesenchymal subtype 
is also unique in its highest expression of CS 6-O-SO3 and ECM molecules including 
collagens, biglycan, and lumican. In summary, the distinct pattern of integrated omics for 
different subtypes may serve as biomarkers for the diagnosis of GBM 4 subtypes.  
5.4.2 Accurate O-glycosylation site assignment for brevican and versican 
 As shown in the Table 5.2 and Figure 5.16, we had difficulty in assigning the 
specific O-glycosylation site precisely and unambiguously when there is multiple S/T in 
the peptide sequence, because the glycan modifications tended to fragment during 
collisional dissociation. In order to maintain the labile glycan modification to the peptide 
backbone, a more gentle fragmentation should be explored like electron transfer 
dissociation (ETD) (120,244) or electron capture dissociation (ECD) (119,121).  In our 
lab, we have FT-ICR mass spectrometer for ECD and RF quadrupole ion trap for ETD. 
Therefore, we are planning to use ECD and ETD fragmentation method to accurately 
assign O-glycosylation sites for brevican and versican in GBM samples. 
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Figure 5.16 Brevican O-glycosylation 
T in red color showed higher chance of O-glycosylation than T in blue color  
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Chapter 6. General Conclusions and Future Perspectives  
6.1 Glycosaminoglycans in human leucocyte  
 Glycosaminoglycans (GAGs) vary widely in disaccharide and oligosaccharide 
content in a tissue-specific manner. Nonetheless, there are common structural features, 
such as the presence of highly sulfated non-reducing end domains on heparan sulfate 
(HS) chains. Less clear are the patterns of expression of GAGs on specific cell types. 
Leukocytes are known to express GAGs primarily of the chondroitin sulfate (CS) type. 
Little is known, however, regarding the properties and structures of the GAG chains, their 
ranges of variability among normal subjects, and changes in structure associated with 
disease conditions. We isolated peripheral blood leukocyte populations from four human 
donors and extracted GAGs. We determined the relative and absolute disaccharides 
abundances for HS and CS GAG classes using size exclusion chromatography-mass 
spectrometry (SEC-MS). We found that all leukocytes express HS chains with level of 
sulfation more similar to heparin than to organ-derived HS. The levels of HS expression 
follows the trend: T Cells, B cells>monocytes, NK cells>polymorphonuclear leukocytes 
(PMNs). In addition, CS abundances were considerably higher than total HS but varied 
considerably in a leukocyte cell type specific manner. Levels of CS were higher for 
myeloid lineage cells (PMNs, monocytes) than for lymphoid cells (B, T, NK cells). This 
information establishes the ranges of GAG structures expressed on normal leukocytes 
and necessary for subsequent inquiry into disease conditions. 
 Heparan sulfate is reported to modulate multiple key steps in the leukocyte 
recruitment cascade during the inflammation process. (245,246). We are surprised to 
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observe extremely high level of sulfation for heparan sulfate in leukocytes, which might 
be important for the leukocyte recruitment as it has higher binding affinities to cell 
surface ligands. In order to better understand the detailed function of highly sulfated HS 
for leukocyte recruitment, we need to figure out the localization and core protein for this 
unique HS structure. Subcellular fractionation experiment will be conducted to locate the 
heparan sulfate proteoglycan. Detailed glycomics and proteomics experiments will be 
applied to characterize the HS structure and HSPG core protein for different subcellular 
fractions. We will also characterize the alterations of HSPGs for activated leukocytes.  
6.2 Multiplexed TMT tags to further increase the throughput of HS/CS profiling 
from histological slides 
 Glycosaminoglycans (GAGs) are found in intracellular granules, cell surfaces, 
and extracellular matrices in a spatially and temporally regulated fashion, constituting the 
environment for cells to interact, migrate, and proliferate. Through binding with a great 
number of proteins, GAGs regulate many facets of biological processes from embryonic 
development to normal physiological functions. GAGs have been shown to be involved 
in pathologic changes and immunological responses including cancer metastasis and 
inflammation. Past analyses of GAGs have focused on cell lines, body fluids, and 
relatively large tissue samples. Structures determined from such samples reflect the 
heterogeneity of the cell types present. To gain an understanding of the roles played by 
GAG expression during pathogenesis, it is very important to be able to detect and profile 
GAGs at the histological scale so as to minimize cell heterogeneity to potentially inform 
diagnosis and prognosis. Heparan sulfate (HS) and chondroitin sulfate (CS) are two 
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major classes of GAGs, characterized by dramatic structural heterogeneity and 
complexity. To demonstrate feasibility of analysis of HS from histological slides, we first 
used SEC-MS to analyze the digested HS disaccharides from frozen brain sections in 
Chapter 3. In order to improve the throughput, we developed HILIC-MS/MS methods in 
Chapter 4 to significantly shorten each LC run to 55 mins and 20 mins for HS and CS 
disaccharides, respectively.  
 
 
Figure 6.1 Sixplex
TM
 TMT tag for high-throughput glycan quantification, adapted 
from Thermo User Manual for aminoxy TMT labeling reagent 
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 In the future, we will test the Thermo carbonyl-reactive aminoxy Sixplex
TM
 TMT 
(tandem mass tag) for mass spectrometry-based quantitative glycomics in order to further 
improve the throughput of the current HILIC-MS/MS method. As shown in Figure 6.1, 
aminoxy TMT tag is composed of a mass reporter, a spacer arm, and a carbonyl-reactive 
aminoxy group, capable of labeling up to 6 biological samples. The primary amine in the 
carbonyl-reactive aminoxy group can react with the aldehyde group of glycans like HS 
and CS disaccharides. The unique reporter mass (126-131 Da) is generated by HCD 
fragmentation in tandem MS and used for quantifying the relative abundances of labeled 
glycans in multiplexed biological samples, representing six different treatment 
conditions, time points, or replicates. With this multiplexed TMT tag platform, the speed 
for glycan data acquisition will increase 6-folds.  
6.3 Comprehensive glycoproteomics analysis for brain ECM molecules 
 In Chapter 5, relatively high abundances of N- and O-glycopeptides were detected 
from our proteomics dataset, without any enrichment strategies for glycopeptides. The 
two major core proteins for mucin type O-glycosylation are versican and brevican, two 
members of the hyalectican class of chondroitin sulfate proteoglycans. The brain ECM, 
which constitutes 10-20% of brain volume, provides a microenvironment for maintaining 
the essential functions of central nervous system (CNS) (243,247,248). The brain ECM is 
also a critical regulator for tumor cell growth and migration and the deregulated ECM 
composition closely correlates with tumorigenesis and neurodegeneration (249-253). The 
major protein components of brain ECM include proteoglycans, glycoproteins, collagens, 
  
127 
and non-collagenous proteins, among which over 80% are glycosylated. However, little is 
known about the detailed glycosylation pattern for brain ECM proteins.  
 In future work, proteoglycans will be enriched with weak ion exchange 
chromatography. Heparin lyases and chondroitinase ABC will be used to cleave the 
glycosaminoglycan chains, producing glycopeptides attached with linker tetrasaccharide 
(GlcA-Gal-Gal-Xyl) or hexsaccharide (ΔGlcA-GalNAc/GlcNAc-GlcA-Gal-Gal-Xyl). N-
glycopeptides will be enriched with HILIC cartridges. Even though there is no universal 
enrichment method for O-glycopeptides, we can selectively enrich sialylated O-
glycopeptides with TiO2 as we observed higher sialylation degree in GBM than in normal 
tissues. The enriched glycopeptides (N-, O-, and GAG-linked) will be fragmented with 
complementary HCD and ETD techniques to determine the glycopeptide sequence and 
glycosylation site(s). 
 Aberrant glycosylations are highly associated with caner progression and play 
fundamental roles in numerous steps of cancer development such as interfering the cell-
cell adhesion, cell-ECM interaction, stimulating RTK signaling pathway, and promoting 
angiogenesis (9,10). Therefore, a comprehensive glycoproteomics analysis for brain 
ECM proteins with the proposed methods will improve our understanding about brain 
cancer pathogenesis.  
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